Hypolipidemic Mode of Action of 3-Hydroxy-3-Methylglutaric Acid by Khan, Rahat Jahan
HYPOLIPIDEMIC MODE OF ACTION OF 
3-HYDROXY -3-METHYLGLUTARIC ACID 
- ^ . %^^ 
ABSTRACT 
THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
IN 
BIOCHEMISTRY 
FACULTY OF SCIENCE 
Aligarh Muslim University, Aligarh 
BY 
RAHAT JAHAN KHAN 
BIOCHEMISTRY DIVISION 
DEPARTMENT OF CHEMISTRY 
Aligarh Muslim University, Aligarh 
1980 
ABSTRACT 
1. The dose-response effects of 3-hydroxy-3-methylglutaric 
acid (HMG) and nicotinic acid were studied on various tissue 
lipids in hyperlipidemic rats. Two doses of HMG (10 mg and 
20 mg) and nicotinic acid (40 mg and 80 mg) per kg body weight 
per day, single and combined were simultaneously administered 
i.p. for 4 weeks. The lower doses reduced significantly serum 
triglycerides only, whereas, the higher doses of these compounds 
significantly decreased both cholesterol and triglycerides in 
serum, liver and aorta. The observed reduction on KMG adminis-
tration seems to be dose-dependent. The combined lov/er doses 
of the two compounds significantly decreased all the lipid 
parameters in all these tissues. The reduction in tissue 
lipids was more marked by the administration of combined 
higher doses of the two compounds. However, the phospho-
lipids remained unchanged by any dose used. The hypolipidemic 
effect by combined doses of HMG and nicotinic acid was found 
to be synergistic. 
2. HMG effectively counteracted the olive oil-induced 
hyperlipidemia within 2-4 hr of its administration. The 
significant decrease in serum triglycerides, free fatty acids 
and phospholipids has been interpreted in terms of the in-
hibitory effect of HMG on VLDL production and intestinal 
absorption of fats. 
(iv) 
3. Administration of HMG for 5 days effectively counter-
acted the diabetogenic action of alloxan in rats. The eleva-
tion of serum cholesterol, triglycerides, phospholipids, 
free fatty acids and blood glucose in diabetes were lowered 
by HMG treatment. Hepatic cholesterol of diabetic rats was 
suppressed. Liver, triglycerides and phospholipids were 
virtually unaltered. The possible mechanism of action of HMG 
in opposing the effects of diabetes is discussed. 
4. HMG reversed the changes in different lipid fractions 
in serum and liver of carbon tetrachloride injected animals 
both in 48 and 168 hour study. Administration of HMG for 
a longer period resulted in a pronounced increase in the 
protective effect of HMG against carbon tetrachloride induced fatty 
liver. This action of HMG might be due to its inhibitory 
effect on depot fat mobilization and/or due to inhibition of 
VLDL production. The liver weight was significantly lowered 
in HMG-treated animals in both the studies indicating a 
beneficial effect of HMG. 
5. Intramuscular administration of cobalt chloride re-
sulted in a marked increase in different lipid levels in 
serum and liver. Treatment of rats with HMG effectively 
counteracted the enhanced lipemic response of cobalt chloride. 
All the lipid parameters decreased significantly in both the 
tissues. It was concluded that the hypolipidemic activity 
of HMG is caused by inhibition of synthesis of VLDL rather 
than the release of VLDL from liver. 
(V) 
6. Age-related alterations in the responsiveness of mature 
rats to HMG were evaluated in 2-3; 5-6; 9-10 and 15-20 months 
old rats. The concentration of cholesterol, triglycerides 
and phospholipids increased with age in serum and liver. 
Administration of HMG for 1 wk caused a decrease in these 
lipids in different age groups. The maximum effect was ob-
served in serum triglycerides in all the groups. Insignificant 
differences in responsiveness between the age groups of 
approximately 3 and 9 month old rats were evident. Several 
mechanisms are probably involved in this phenomenon, including 
alteration in the compound distribution, metabolism, elimina-
tion and target organ sensitivity. 
7. Oral administration of HMG for 1 wk to normocholesterol-
emic chickens significantly lowered seriom cholesterol and 
triglyceride levels. The free fatty acids and phospholipids 
were insignificantly decreased. The lipid lowering action of 
HMG does not appear to be species-specific. 
8. HMG significantly prevented the rise in serum 
cholesterol, triglycerides and phospholipids in Triton-in-
duced hyperlipidemic chickens. An insignificant effect was 
found in free fatty acids. HMG effectively counteracted the 
hyperlipidemic response only when given along with Triton. 
The possibility of HMG exerting its hypolipidemic effect 
through the inhibition of lipoprotein synthesis appears more 
Plausible. 
(vi) 
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PREFACE 
What causes heart attacks? A host of reasons have 
been cited by biological scientists in the past heredity, 
obesity, tension, smoking, lack of exercise, coffee drinking 
etc. Today biochemist's opinion is veering around to the 
view that the most important causative factor may be high 
blood cholesterol. Heart disease has been identified as 
number one killer in the United States, although it may be 
a more serious problem for under developed countries like 
India where industrialization is rapidly changing the life 
style. Retrospective and prospective studies have dociimented 
the close association between hyperlipidemia and the incidence 
of coronary heart disease (CHD). The implication of blood 
lipids as a contributing factor in the pathogenesis of 
atherosclerosis has led to a wide search for effective 
measures which control the concentration of cholesterol and 
triglycerides in blood and other tissues. 
Numerous physiological and non-physiological lipid 
lowering agents have been investigated but due to side effects 
their fate in the successful chemotherapy of atherosclerosis 
and allied diseases is still debated. It is believed that an 
inhibitor of cholesterol biosynthesis, acting prior to HMG-
CoA reductase step which is considered to be the main 
regulatory point in hepatic cholesterogenesis, cannot be 
(i) 
successfully used as a hypocholesterolemic drug because it 
would also affect other important metabolic reactions of the 
body. 3-Hydroxy-3-methylglutaric acid (H4G) fozmed in vivo by 
deacylation of HMG-CoA, has been shown to inhibit bacterial 
HMG-CoA reductase- In extensive studies in rats, rabbits and 
man, HMG has been found to possess potent hypolipidemic activity. 
The so far completed study show that compared to other hypo-
lipidemic compounds, relatively small doses of HMG (20 mg/kg) 
cause maximum cholesterol and triglyceride decrease in serum 
and serum g-lipoproteins of mammalian system. It is believed 
that the mechanism of action of HMG in inhibiting the de-
velopment of atherosclerosis might involve a shift of lipo-
protein spectrum which may also partially be responsible for 
decreased cholesterol deposition in liver. However, in re-
ducing serum cholesterol, an increased rate of excretion of 
cholesterol and/or its metabolite cannot possibly be excluded. 
Taking into account the potential hypolipidemic propeirties of HMG 
in rats and rabbits, and the effectiveness of this compound 
in the treatment of familial hypercholesterolemia, the pre-
sent investigation has been directed to elucidate the possible 
mode of action of HMG. The following studies have been carried 
out. 
(I) Dose-response effect of single and combined HMG and 
nicotinic acid treatment in hyperlipidemic rats. 
(II) Effect of IMG on intestinal absorption of fat (olive 
oil-induced hypertriglyceridemia). 
(ii) 
(III) Protective effect of HMG in alloxan-induced diabetes 
in rats. 
(IV) Effect of HMG in preventing carbon tetrachloride-
induced fatty liver in rats. 
(V) Effect of HMG on cobalt chloride-induced hyper-
lipidemia in rats. 
(VI) Age-related responsiveness of rats to hypolipidemic 
action of HMG. 
(VII) Effect of HMG on serum lipids of noimocholesterolemic 
chickens. 
(VIII) Effect of HMG on serum lipids of chickens treated 
with Triton WR-1339. 
(iii) 
C H A P T E R 
I N T R O D U C T I O N 
GENERAL 
Hyperlipidemia means too much lipid in the blood. 
At first sight this seems simple and straight forv;ard, but 
in fact it is not. The situation is complicated because -
1. There are several different plasma lipids. 
2. The plasma lipids do not occur in free form but are 
combined with proteins to form lipoproteins i.e., 
the condition can be better described as hyperlipo-
proteinemia (HLP) . 
3. "Too much" is very difficult to specify since we 
can not easily define normal values. 
Most of the lipids in plasma are present as lipo-
proteins (Fredrickson et_ a]^. , 1967) . The levels of these 
lipoproteins are subject to dynamic changes. In hyper-
lipidemic conditions the concentration of one or more type 
of lipoproteins are elevated. The major lipoprotein families 
separated according to electrophoretic mobility or density, 
are inter-related within a complex metabolic system. The 
biosynthetic pathway of very low density lipoproteins 
(VLDL), low density lipoproteins (LDL) and high density 
lipoproteins (HDL) is of particular interest in the study of 
hyperlipoproteinemia and hypolipoproteinemic drugs. 
Retrospective and prospective studies have documented 
a close association between hyperlipidemia and the 
incidence of coronary heart disease (CHD). Since only 
plasma cholesterol has been determined in most of these 
studies, it is not yet clear which type or types of 
hyperlipoproteinemia are most associated with CHD. From 
these studies and from those of Ghirardi e_t al_. (1972) and 
Tzagournis, (1978), it is clear that not only plasma 
cholesterol but also fasting plasma triglycerides, with or 
without concomitant plasma cholesterol elevation, are 
closely associated with CHD. This indicates that elevation 
of the triglyceride rich VLDL is also involved in the 
association between CHD and HLP. 
More than seventy years ago, the field of experimental 
atherosclerosis was opened by the studies of Ignatowski (1909), 
Since then, much efforts have been devoted to elucidating the 
mechanisms of genesis and the underlying causes of the 
atherosclerotic process by reproducing the disease in animals. 
Atherosclerosis has been defined by the World Health 
Organization, as a "variable combination of changes of the 
intima of arteries consisting of the focal accumulation of 
lipids, complex carbohydrates, blood and blood products, 
fibrous tissues and calcium deposits associated with medial 
changes". Atherosclerosis is, therefore, a complex and 
multifaceted condition which may be collection of pathological 
states with overlapping similarities of arterial 
abnormalities. Generally atherosclerosis either of aorta 
or of coronary arteries involves the formation of lipid 
deposits inside the walls of blood vessels. The developing 
atheroma has many of the features of a specific granulomat-
ous lesion (Kaunitz, 1978). The early changes of the 
mesenchyma have been particularly well studied by Hauss 
(1973). The intima is invaded by smooth muscle cells 
(Koss and Glomset, 1973; Benditt, 1977). Gradually the 
characteristic plaque develops made up of the modified smooth 
muscle cells, collagen, debris from, dying cells and varying 
amounts of lipids including cholesterol. The forerunner of 
atherosclerotic lesion can be recognized in the form of 
fatty streaks. It is believed that 90% of all genuine 
forms of angina pectoris and myocardial infarction are 
associated with sclerotic changes in the coronary artery 
(Schettler, 1961) . The arteries afflicted with athero-
sclerosis exhibit thickening of the arterial wall intima, 
usually hypertrophy of the media with clearly demonstrable 
lipid deposits. Since all these factors lead to decrease 
in the size of arterial lumen, it results in the 
restriction of flow of blood at reasonable pressures. Thus 
the restricted supply of oxygen and nutrients to coronary 
muscle leads to diminished performance and finally heart failure 
A. EPIDIMEOLOGY OF ATHEROSCLEROSIS 
It is now well recognized that a number of "risk 
factors" may be involved in the development of athero-
sclerotic heart disease. These factors include hyperchol-
esterolemia (serum cholesterol, 260 mg/100 ml or above), 
hypertension (diastolic blood pressure of 95 mm or above), 
marked obesity, heavy cigarette smoking, diabetes mellitus, 
and a family history of vascular disease (Kannal et al^ . , 
1971; Lewis and Naito, 1978). 
A number of undeniable facts have emerged which do 
show that cholesterol is somehow associated with degenerative 
disease. 
(i) Atherosclerotic plaques contain large amounts 
of cholesterol and its esters; 
(ii) Persons with sufficiently elevated serum 
cholesterol values have a higher risk of 
developing such atherosclerotic complications 
as heart attacks and strokes; 
(iii) Disease associated with high serum cholesterol 
levels (e.g., nephrosis) are associated with 
pronounced atherosclerotic lesions and 
(iv) Feeding of cholesterol to some mammalian 
species induces deposition of cholesterol in 
many tissues including arteries. 
B. DIET AND ATHEROSCLEROSIS 
A number of epidemiological and nutritional studies 
suggest a correlation between CHD and diet. Increase in 
CHD has been linked with increase in consumption of dietary 
components viz; cholesterol, animal protein and carbo-
hydrates. Hyperlipidemia is produced by a variety of 
factors including increased absorption of dietary fat, 
altered transport of plasma lipids and changes in the 
composition of plasma lipids. Although the metabolic 
implications of each of these factors, as well as their 
possible relationship to atherogenesis differ, they have 
all formed the basis of a variety of systems for the listing 
of blood-lipid lowering agents. To some extent it is possible 
to produce experimental hyperlipidemia with predominant 
elevation of a given lipid class, although the lipid 
distribution is governed mainly by the composition of the 
type of lipoproteins that are elevated. 
Atherosclerosis has been induced in rabbits (Kritchevsky, 
1964; Constantinides, 1965), chickens (Dauber and Katz, 
1942) monkeys (McGill et al., 1961), dogs (Steiner and 
Kendall, 1946) and pigs (Downie et^  al. , 1962) by 
cholesterol feeding. Kritchevsky et. al^ . (1971) reported 
that rabbits fed a diet containing coconut or peanut oil 
with 2% cholesterol had the most extensive as well as the 
most frequent and severe lesions than that of corn oil. 
The corn-oil containing diet was less atherogenic than 
lard or butter oil, native or randomized, which have 
virtually no difference as regards their atherogenic 
potential (Kritchevsky and Tapper, 1977), It has been 
found that saturated fats along with cholesterol produced 
more severe atheroma than unsaturated fats (Kritchevsky 
and Tepper, 1967). Atherosclerosis can also be produced 
in rats within 5 days by intubating a mixture of cholesterol 
and vitamin D2 in olive oil (Altman, 1973). There is a 
recent evidence for a more rapid metabolism of the 
abnormal cholesterol rich VLDL as compared to the control 
VLDL. The effect was found more pronounced in the lipoprotein 
fractions isolated from rabbits fed additional coconut or 
corn oil to their cholesterol enriched diets (Stange et_ a_l. , 
1975; 1977). This suggests significant implications on the 
atherogenecity of lipoproteins emphasizing their role in 
experimental atherosclerosis (Smith, 1978). 
Recent evidences have shown that diets high in 
protein have a tendency to elevate the level of serum 
cholesterol (Carroll, 1978 a). It has been suggested that 
hypercholesterolemia has been related mainly to the use 
of casein as the source of protein (Carroll and Hamilton, 
1975; Hamilton and Carroll, 1976). Other studies have 
provided evidence that a change from animal protein to 
plant protein in the diet is associated with a decrease 
in the level of seriom cholesterol (Sirtori, 1977). It has 
been suggested that the level of plasma cholesterol in 
humans may be influenced by the kind of dietary protein as 
well as the amount in the diet (Carroll, 1978 b). 
By feeding starch, sucrose, fructose, glucose or 
maltose containing diets, Naismith and Khan (1970 a, 
1970 b) showed that animals eating simple sugars have 
higher triglyceride levels than those eating starches. This 
has been further confirmed by Nagarajan (1971) who showed 
14 greater incorporation of C labelled sucrose, glucose, 
fructose into glyceride fraction in baboons. In experiments 
of this kind, carried out with several species including 
rats, spiny mice, pigs, and man, diets with sucrose 
produced an increase in the concentrations of 
plasma cholesterol, triglyceride, and uric acid; a 
dimunition in glucose tolerance; an increased platelet 
adhesiveness; and a change in electrophoretic behaviour 
of platelets (Yudkin, 1972). In view of recent findings 
there is a stronger case for implicating sucrose in 
causing CHD than for implicating fat (Besset and Schroffner, 
1968; Yudkin, 1978). 
C. ABSORPTION AND METABOLISM OF FATS 
For a number of years, investigations on the 
mechanism of fat absorption by the intestine have been 
primarily concerned with the analysis of the contents of 
the digestive tract and thoracic duct lymph following a 
fat meal. Dietary fat is absorbed after partial hydrolysis 
in small intestine. After reesterification to form 
triglycerides, it is packaged into spherical droplets 
(chylomicrons) in which the fat is coated with a monolayer 
of phospholipids, specific proteins and cholesterol. These 
droplets enter the lacteals of intestinal villi and are 
transported through the lymphatic system to the blood. Upon 
reaching the capillary bed of several extra-hepatic tissues, 
the chylomicrons are absorbed into the endothelial surface. 
As a result of the action of lipoprotein lipase the trigly-
cerides are hydrolysed and liberated fatty acids are taken up 
locally into the tissues to be esterified and thus stored and 
oxidized for future energy needs. Alternatively, these fatty 
acids can recycle as free fatty acids in blood and enter 
tissues elsewhere. 
10 
Transport of exogenous triglycerides in chylomicrons 
is highly efficient so that chylomicronia ensues within few 
hours after each fatty meal. In states of genetically 
determined or acquired deficiency of lipoprotein lipase the 
capacity to transport triglycerides is quite limited and 
chylomicronia may persist from meal to meal (exogenous 
hyperlipidemia). In other more common forms of hyperlipidemia, 
not accompanied by over deficiency of lipoprotein lipase, the 
capacity to transport triglycerides in VLDL appears to be 
limited specifically (endogenous hyperlipidemia) so that 
concentration may be substantially increased when rates of 
production are in the normal range. 
The level of VLDL and its constituent triglycerides 
can be affected by hormones that increase (norepinephrine, 
growth hormone) or decrease (insulin) the supply of fatty 
acids used for hepatic triglyceride synthesis. Insulin 
affects the level of triglyceride-rich lipoproteins by 
influencing the activity of lipoprotein lipase in extrahepatic 
tissues (Havel, 1965).Thus, the pathway of transport of trigly-
cerides in blood plasma and its regulation provides a reasonably 
firm basis for evaluating the action of drugs that reduce 
triglyceride levels. 
D. DIABETES AND ATHEROSCLEROSIS 
It is well established that diabetes increases 
the risk of atherosclerosis in coronary, cerebral and 
peripheral arteries (Garcia et ai^. , 1974; Keen et a_l; 1965). 
The coronary arteries and abdominal aorta of diabetics 
showed more atherosclerosis than non-diabetics regardless 
of age, sex, race and geographic location (Robertson and 
Strong, 1968). However, there is little evidence that 
within the diabetic population the frequency of large 
vessel complications is related to the degree of hypergly-
cemia, and treatment of hyperglycemia has not been shown 
to be protective against arterial disease (Stout, 1975) . 
Hypertriglyceridemia is a common abnormality in diabetics 
(New et_ al^ . , 1963) and is associated with atherosclerosis 
in diabetes (Santen et^  al^ . , 1972). Elevated insulin levels 
found in many diabetics are related with other metabolic 
abnormalities such as obesity (Porte and Bagdate, 1970) , 
hypertriglyceridemia (Bierman e_t al^ . , 1970), and Uracemia 
(Bagdate, 1970). Chronic exposure to high concentrations 
of insulin results in the development of lipid filled lesions 
similar to those of early atherosclerosis (Renold et al^ . , 
1968; Stout, 1977). Insulin has the ability to promote 
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changes in the artery which, in the long term may progress 
to atherosclerosis (Stout, 1977). 
Several groups of investigators have attempted 
to develop experimental models of diabetes. On the assumption 
that diabetes is a disease of absolute insulin deficiency, 
insulin secretion from the pancreas was ablated, either with 
the use of chemicals such as alloxan and streptozotocin, or 
by surgical removal of the pancreas. Alloxan or streptozotocin 
induced diabetic animals showed marked changes in lipid 
metabolism, especially an elevation in serum triglycerides 
(Meier et_ al_., 1972) and a decrease in hepatic cholesterol 
synthesis (Corder and Kalkhoff, 1969). These compounds are 
selectively taken up by the insulin-producing 3-cells of the 
pancreas and subsequently cause their destruction (Rerup, 1970), 
Previous work on the lipid levels of various tissues in alloxan-
induced diabetes include decrease in the phospholipid of brain 
but not of liver (Karagezyan, 1968); increase in the free 
fatty acids and glycerides of the heart (Rizza et_ al_. , 1971) ; 
increased deposition of cholesterol in the retina (James and 
Alan, 196 3); increase in cholesterol, phospholipid and 
triglyceride of liver (Malathy and Kurup, 1972) and increase 
in the lipid acciimulation in the arterial wall ( Stout, 1973; 
1977). A decrease in lipoprotein lipase activity in liver 
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has been reported in diabetic rats (O'Conner e_t £l_., 1968; 
Malathy and Kurup, 1972). No change in lipoprotein lipase 
activity was observed by Shigeta et_ al_. , (1970), while 
Malathy and Kurup, (1972) found an increase in the enzyme 
activity in the heart. An increased myocardial enzyme 
activity was reported by Bondarenko (1970). Many hypolipid-
emic agents are known that inhibit the diabetogenic effect 
of alloxan and streptozotocin in rats (Benerji, 1947; 
Lazarow et al, 1950; Cayen, 1975; Duhault, 1976). 
E. FATTY LIVERS 
One experimental approach in the study of regulation 
of lipoprotein metabolism is through exploration of the 
mechanism of fatty liver production. Recknagel et a_l. (1960) 
suggested that a defect in excretion of lipids in the 
form of 3-lipoproteins may be the underlying mechanism of 
fatty liver development. Inhibition in synthesis of the 
protein moiety of 3-lipoproteins is the mechanism responsible 
for induction of fatty liver in response to several 
hepatotoxic drugs (Farber, 1966). An inverse relationship 
between hepatic triglyceride accumulation and serum lipoprotein 
concentration has been demonstrated in rats treated with 
puromycin (Robinson and Seakins, 1962), ethionine (Ugazio and 
Lombardi, 1965) and carbon tetrachloride (Rechnagel, 1967). 
However, synthesis of lipoproteins and their release from 
the liver appears to be a complex process (Oler and Lombardi, 
1970) . Feeding of orotic acid results in the development 
of fatty liver in rats (Standerfer and Handler, 1955; 
Handschumacher et^  a 1, 1960) . This phenomenon unlike the 
development of fatty liver induced by choline deficient diet 
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does not seem to be accompanied by other serious pathological 
disturbances and is readily reversible. The feeding of 
orotic acid in diet selectively interferes with synthesis 
and/or release of VLDL without having any general effect on 
hepatic protein synthesis or on the release of other serum 
proteins synthesized in liver (Windmueller, 1964; Sidransky 
et al,, 1963). 
The adrenalectomy (Wool et_ al^ . , 1954; Brody et^  al., 
1961) and adrenergic blocking agents (Brody et^  a_l. , 1961; 
Schotz and Page, 1959) have been found to prevent carbon 
tetrachloride and ethionine - induced fatty liver. It has 
been shown that administration of adenine or its nucleotide 
derivatives prevent the induction of fatty liver by ethionine, 
carbon tetrachloride, orotic acid (Handschumacher ejt al. , 
1960) and pectamycin, but failed to relieve inhibition of 
protein synthesis in vivo and the derangement of triglyceride 
transport from liver caused by the hepatotoxins (Glaser and 
Mager, 1972). According to Recknagel and Lombardi (1961) the 
formation of triglycerides by the liver is not interfered 
within the carbon tetrachloride poisoned animals, but the 
hepatic triglyceride secretory mechanism is inhibited. As 
a result, triglycerides accumulate in liver. It was first 
observed that carbon tetrachloride reached its peak 
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concentration in the liver of the rat within 1 to 2 hours 
after force feeding of the hepatotoxin (Recknagel and 
Litteria, 1960). The hepatic content of triglycerides was 
elevated 34% within 1 hour and 195% within 3 hours after 
carbon tetrachloride poisoning. This observation indicated 
that a serious derangement of hepatic lipid metabolism 
occurred coincident with the arrival of the toxic compound 
in the liver. A series of investigations (Recknagel and 
Anthony, 1959; Share and Recknagel, 1959) had previously 
led to the tentative conclusion that the hepatic parenchymal 
cell mitochondria were probably not the primary loci for 
the attack by carbon tetrachloride. The observation that 
carbon tetrachloride feeding results in pathological changes 
in the enzymatic properties of the microsome fractions at 
a time when the toxin is concentrated in the liver, and 
when rapid accum.ulation of triglycerides in the liver is 
taking place, suggested that the hitherto unknown hepatic 
mechanism, intimately associated with hepatic lipid metabolism 
and probably localized in the membraneous component of the 
endoplasmic reticulum, was most probably the key locus involved, 
F. COBALT CHLORIDE - INDUCED HYPERLIPIDEMIA 
Cobalt chloride has been known to produce 
hyperlipidemia in both man (Robey, et^  al_. , 1956) and 
animals (Munoz-Calvo et_ aJ^ . , 1973; Kavacev et_ al. , 1977) . 
Several clinical reports of cobalt-induced goiter in 
human patients have made casual reference to the increased 
serum lipid values determined in the patients (Caren and 
Carbo, 1956; Carlson, 1963). Cobalt ion produces an 
endogenous hyperlipidemia which is virtually indistinguishable 
from "carbohydrate-induced lipemia" and is independent of 
dietary considerations (Eaton and Kipnis, 1969 a; 1969 b ) . 
The endogenous hyperlipidemia of both carbohydrate feeding 
and cobalt chloride treatment is initiated by insulin 
mediated stimulation of hepatic protein synthesis followed 
by release of the lipid carrying protein into the circulation 
(Eaton, 1972) . The serum of rabbits was characterized as 
grossly lipemic with the predominant abnormality being an 
increase in VLDL transport protein and its triglyceride 
component. This led to the belief that cobalt chloride 
induced lipidemia may be secondary to changes in the 
T.etabolism of carrier protein. Daily intramuscular 
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injections of cobalt chloride to male rabbits for three 
days has been found to increase lipids, glucose and 
blood insulin levels in blood plasma and glucose-stimulated 
insulin secretion (Ohm:ichi,ejt aJ^ -, 1974). The oral 
administration of cobalt chloride at the level of 10 mg/kg/ 
day to male rabbits for 12-36 days increased the levels 
of cholesterol and 3-lipoproteins in the blood serum; 
decreased the fat level in the liver and inhibited the 
lipolytic activity of the aorta wall and adipose tissues. 
A decrease in aorta wall lipoidosis was also observed 
(Lempert and Levina, 1974). When given orally at a dose 
of 3-6 mg/kg/day to rabbits with atherosclerosis induced 
by cholesterol, the effects on neutral fats and 3-lipoproteins 
in serum were more pronounced (Boechko, 1972) . Cobalt 
chloride, 25 mg/kg/day i.m. increased the blood plasma 
triglyceride level and turnover rate in rabbits. There was 
no change in lipoprotein lipase activity but there was an 
increase in liver triglycerides. It was suggested that the 
increase in blood plasma triglycerides caused by cobalt is 
a result of release of triglycerides from the liver (Morita 
et a]^. ,1974). Plasma triglyceride concentrations in rats 
receiving cobalt chloride 40 mg/kg, s JC • for 10 days with an 
interruption of 9 days after the first injection was two-fold 
higher than in control rats, and the increased level of 
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triglycerides was maintained for at least one year. The 
increase in cholesterol and free fatty acids developed 
more slowly. Plasma triglyceride levels of anephric 
patients was increased during cobalt tretment, but 
unlike the level in rat plasma, the triglyceride level 
fell slowly toward the basal level after cessation of 
cobalt treatment (Taylor et_ al. , 1977) . Cobalt chloride 
also increased hepatic L-glycerophosphate and hepatic 
acyl CoA, and induced hyperglycemia and hypertriglyceridemia 
and increased plasma insulin levels. (Ohmichi, 1977). 
G. TRITON-INDUCED HYPERLIPIDEMIA 
The non-ionic detergent Triton WR-13 39 injected 
intravenously, produces hyperlipidemia in rats 
(Nityanand and Kapoor, 1973), rabbits (Kellner et. al., 
1951 a), mice (Cornforth et. aj^. , 1951) and in monkeys 
(Kapoor and Nityamand, 1975). Yamada et_ al^ . , (1966) 
reported a species difference in Triton induced 
hypercholesterolemia which was greater in rabbits than 
in rats, dogs and mice. Triton is believed to form a 
surface layer around lipoproteins and thereby protect 
them from enzymatic modification, specifically, in the 
case of VLDL, from hydrolysis by lipoprotein lipase. The 
marked hypertriglyceridemia has been attributed to failure 
of triglycerides to leave the plasma compartment (Lombardi 
and Recknagel, 1962). The lipids mobilized from tissue 
stores and bound in the plasma compartment by Triton are 
not metabolized, but may be deposited in the vessel wall. 
This process was demonstrated to occur in dogs and treatment 
with Triton was found to result in early atheromatosis 
(Scanu e_t al^ . , 1961). In rabbits (Kellner et_ aj^., 1951 b) 
and rats (Still, 1962; Hess and Loustalot, 1963) the 
development of vascular lesions has been found to be 
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hindered by Triton in spite of the presence of hyperlipidemia. 
Triton injected intravenously, has frequently been 
used to determine rates of triglycerides secretion into the 
plasma of experimental animals (Reaven et_ al_., 1973). 
Illingworth et_ a^, (1975) found that intravenous infusion 
of Triton WR-1339 (300 mg/kg body weight) increased plasma 
triglycerides almost linearly for 9-12 hours. Analysis of 
individual lipoproteins separated by ultracentrifugation 
showed that newly secreted triglycerides were present almost 
exclusively in the low density lipoprotein fraction. 
Illingworth (19 75) also reported that in short-teirm experiments 
(3-6 hr) the detergent does not affect the rate of synthesis 
or secretion of these macromolecules into the circulation. 
Byers et_ al^  (1963) also failed to demonstrate any difference 
14 in the incorporation of C-acetate into hepatic cholesterol 
from normal and Triton-treated rats 90 minutes after Triton-
infusion; after 24 hr, however,cholesterol synthesis was 
increased in the Triton-treated animals. The Triton two-phase 
system has been used by Garattini et_ al^ . (1961) and Paoletti 
(1962) for testing potential hypolipidemic agents. Schurr 
et al., (1972) used Triton i;vR-1339 induced hyperlipidemia in 
rats as a screening model for various hypolipidemic agents.. 
H. TREATMENT WITH DRUGS 
Though proof is still lacking, a considerable body 
of clinical and experimental evidence support the idea that 
correction or lowering of elevated plasma lipid levels may-
have a beneficial effect in the treatment of CHD (Levy and 
Fredrickson, 1970; Kannel et a]^. , 1971). It is well known 
that effective inhibitors of cholesterol biosynthesis will 
lower not only cholesterol levels but also the levels of 
lipoproteins. Among the possible sites, interference with 
rate-limiting step in biosynthesis (EMG-CoA to mevalonic 
acid seems to be the most promising one (Gould, 1960; 
Migicovasky, 1962). The other possibilities, i.e., 
stimulation of cholesterol excretion and its degradation 
to bile acids, inhibition of absorption of dietary 
cholesterol, absorption or resorbtion of biliary cholesterol 
appear less feasible. A compound capable of lowering 
cholesterol may effect either one or more than one of the 
above processes. 
Dietary regimes and drugs are the main methods used 
for reducing elevated plasma triglyceride or cholesterol 
levels in primary HLP. The former is often regarded as the 
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primary treatment of choice to be supplemented only if 
necessary by one or more drugs. Other types of treatments 
are small bowel resection and shunt operations, particularly 
effective in Type IIA HLP. In most cases, dietary treatment 
has to be supplemented by drugs to obtain substantial results. 
Much has been learned about lipid transport physiology 
and lipid disorders in recent years. This in turn has shed 
light on the effect and mechanism of hypolipidemic agents. 
Table 1 gives a partial list of major hypolipidemic compounds 
in which the current interest continues. 
1. Single Drug Treatment 
Cholestyramine; Cholestyramine is a copolymer of divinyl-
benzene with trimethylbenzylammonium groups, providing the 
exchange sites. It is hydrophillic but insoluble in water 
and remains unchanged in the gastro-intestinal tract. It acts 
by binding bile acids in the intestinal lumen and thereby 
preventing their resorbtion and promoting their excretion in 
the faeces. These sequestrating agents thus interfere with 
the enterohepatic circulation of the bile acids. As these 
are synthesized in liver from cholesterol, cholesterol 
catabolism is accelerated and as an effect plasma cholesterol 
concentration decreases. Cholestyramine was first used in 
patients with cholestasis in whom, distressing pruritis 
prompted efforts to lower the content of bile acids in plasma 
(Carey, 1961). 
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Table 1. Hypolipidemic Compounds 
I. Inhibitors of Cholesterol Absorption 
Bile acid-binding resin (Cholestyramine*) 
S-Sitosterol (Cytellin*) 
Neomycin 
Brain extract (Cerebrosides) 
Aluminium oxide (Gelusil) 
Androgenic steroids 
Competing sterols (Dihydrocholesterol) 
II, Inhibitors of Cholesterol Biosynthesis 
Phenylbutyrates (Clofibrate, CPIB*) 
Nicotinic acid (Heparinoid*) 
3-Hydroxy-3-methylglutaric acid (HMG) 
Triparanol (MER-2 9) 
Aza sterols (7-Aza-5 3-cholestan-3 3-ol) 
Ubiquinone 
Hydroxylamines (Benzyloxy acetamide) 
Cholestane-triol analogues 
Benzmalacene 
III. Enhancement of Cholesterol Excretion 
Thyroactive substances (D-thyroxin*) 
Salicylates 
Linoleamides 
Sulfaguanidine 
Calcium carbonate 
Nafoxidine HCl 
Lipotropic agents (Choline) 
IV, Unknown Mechanisms 
Mucopolysaccharides (Mucin) 
Phenothiazines 
Vanadium 
Biochanin A 
Formononetin 
* Clinically useful compound; commercial, common or 
specific names are given in parentheses. 
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Interest in the application of bile acid-binding resins 
in the treatment of hyperlipidemia quickly followed the 
demonstration that cholestyramine was effective in 
lowering of cholesterol and incidence of coronary athero-
sclerosis in cholesterol fed cockrel (Tennent et_ aJ^ . , 1960) 
and atherogenic diet fed rats and rabbits (Beher et^  al_. , 
1967). Plasma LDL levels decrease after treatment with 
cholestyramine while VLDL concentration may remain unchanged 
or increase (Levy et ajL_. , 1972). Treatm.ent with 4 gm 
cholestryamine for two months decreased plasma cholesterol 
concentrations by 21% in Type II A and II B hypercholesterolemic 
patients (Carlson and Olsson, 1974). The effect of choles-
tyramine on serum lipids in patients with familial hyperbeta-
lipoproteinemia has been evaluated in several short term 
studies (Jones and Dobrilovic, 1970; Levy et_ a]^. , 1972). The 
average reduction of total plasma cholesterol in the 60 
subjects of these studies, who received 12-24 gm of resin per 
day is 25%. Reductions of LDL cholesterol of 27% and 40% 
were observed on daily doses of 16 gm and 32 gm respectively. 
Cholestipol, an insoluble tetraethylenepentamine and 
epichlorohydrin co-polymer is a new anionic bile sequestering 
resin which decreases resorbtion of bile acids and enhances 
their faecal excretion (Parsons, 1972). By increasing the 
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faecal excretion of bile acids, cholestipol brings about 
a compensatory increase in cholesterol production rate and 
an acceleration of its turnover. This results in a 
reduction of total cholesterol in tissue and plasma 
(Goodman et al_.,1973; Miller et_ al. , 1973). Recent studies 
have shown that cholestipol lowers plasma cholesterol 
levels in man and animals (Glueck et al^ . , 1972; Fellin 
et al., 1975). The major drawback to the use of bile 
sequestering resin is the necessity of ingesting large 
doses of unpleasant tasting material. It also causes 
constipation, nausia, bloating and methiorism in patients. 
Nicotinic Acid and Derivatives: Nicotinic acid has been a 
consistently effective lipid lowering agent, when given in 
dose exceeding its requirement as a vitamin. Altschul 
(1956) found that the administration of nicotinic acid 
inhibited the development of both hypercholesterolemia 
and atheromatosis in cholesterol fed rabbits. It is now 
clear that plasma triglyceride levels are also markedly 
reduced by nicotinic acid (Carlson et_ a_l. , 1968). In 1962, 
Carlson and Oro found that nicotinic acid caused a rapid 
and transient fall in the concentration of plasma free 
fatty acids, followed by a rebound. It was suggested 
that the reduction of free fatty acids may partly be the 
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cause of the reduction of plasma triglyceride and 
cholesterol levels. It was proposed that nicotinic acid 
inhibited mobilization of free fatty acids from adipose 
tissues. This reduced the uptake of free fatty acids 
in liver which resulted in decreased hepatic formation 
of VLDL. The consequences of these events would be to 
reduce the conversion of VLDL and eventually diminution 
of LDL level in plasma with the result that plasma 
cholesterol and phospholipids would be lowered. It appears 
that nicotinic acid effects the biosynthesis of cholesterol, 
probably prior to the cyclization of squalene (Goldsmith, 
1962). There is also the possibility that nicotinic acid 
may act prior to the formation of mevalonic acid (Gamble 
and Wright, 1961). Barboriak and Meade (1971) showed 
reduction of usual alcohol induced enhancement of 
alimentary lipidemia in man by nicotinic acid administration. 
Similar results were also obtained in rats when they were 
given a corn oil-alcohol mixture by gastric intubation. 
14 Under these conditions less incorporation of C-labelled 
dietary fat into plasma triglycerides was observed. 
Nicotinic acid, 3 gm daily, reduces plasma triglyceride 
and cholesterol levels by about 50-60% in Type III while 
it may reduce plasma triglycerides by 90% or more in Type 
V HLP (Carlson and Oro, 1973). Subcutaneous injection of 
nicotinic acid lowers the plasma VLDL and LDL concentrations. 
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but has no effect on plasma HDL in rhesus monkeys. It 
14 
also diminishes the maximum incorporation of C-labelled 
threonine into VLDL and LDL apoproteins, but has no 
effect on incorporation into albumin or HDL apoproteins 
(Amany et_ a]^., 1975). The Coronary Drug Project (1975) 
reported that nicotinic acid was the only hypolipidemic 
drug studied which significantly reduced the frequency 
of non-fatal recurrent myocardial infarction and cerebral 
vascular incidents. One advantage of nicotinic acid over 
clofibrate is that there is a dose-response relationship 
as far as the plasma lipid lowering effect is concerned. 
Benerji (1947) found that nicotinic acid, pyridinedicar-
boxylic acid and 2-Phenyl-quinolin-4-carboxylic acid are 
protective against alloxan diabetes. Lazarow et_ al. , 
(1950), later on, confirmed that nicotinic acid in fact 
protected if given 60 minutes before alloxan. Nicotinamide 
but not nicotinic acid, was effective even if given 
immediately before alloxan, but only if the dose was increased 
about three times. The most common side and annoying effects 
of nicotinic acid therapy is intense cutaneous flushing and 
pruritis which generally develops within one to two hours of 
the dose. More troublesome effects may include gastrointestinal 
complaints, gastric distress, dispepsia, hyperuricemia and 
decreased glucose tolerance. 
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Many derivatives of nicotinic acid reduced the serum 
lipids without definite side effects. Complamin, a deriva-
tive of nicotinic acid, decreased blood cholesterol as well 
as other lipids (Blanco et^  al^ . , 1963). Among nicotinic, 
nicotinuric and 3-pyridine acetic acid (100-250 mg/kg) given 
intraperitoneally to hyperlipidemic rats, nicotinuric acid 
was most effective (Brus, 1967). 2,2,6,6-tetrakis (nicotinonyl-
oxymethyl) cyclohexanol (K-31) has been reported to suppress 
the elevation of serum cholesterol, phospholipid and trygly-
ceride levels, but only cholesterol and phospholipids in 
liver (Aso et_ al_. , 1969). The hypochlolesterolemic action of 
K-31 may be due to inhibition of exogenous sterol absorption. 
Another derivative of nicotinic acid, pentaerythritol tetra-
nicotinate (perycit) has been shown to possess hypolipidemic 
properties in high fat high cholesterol-fed rabbits (Brattsand 
and Lundholm, 1971). They showed that perycit reduced the rise 
in free and esterified cholesterol and triglycerides of seriim. 
Perycit appeared generally to be somewhat more effective than 
nicotinic acid in reducing lipid infilterated area of aorta. 
Increase in dose of perycit (3 gm to 4.5 gm) caused a decrease 
in plasma lipid levels. In fat-fed rabbits, both drugs had a 
hypolipidemic and antiatherosclerotic effect when the plasma 
cholesterol value was below 1200 mg/lOOml (Brattsand, 1975a). 
The antiatherosclerotic effect of niceritrol was partly 
attributed to its hypocholesterolemic effect, but it also 
seemed to have a more direct action on the vascular wall 
30 
(Brattsand et_ aJ^. , 1974; Brattsand, 1976). The reduction of 
plasma triglyceride and cholesterol concentrations can also be 
explained by decrease in VLDL triglyceride and cholesterol 
concentrations. The cholesterol concentration decreased in 
low density fraction but increased in high density fraction 
(Olsson et^  al^ . , 1974). In a recent comparative study of 
nicotinic acid, niceritrol and S-pyridylcarbinol in guinea pigs 
fed hypercholesterolemic diet, 0.5-0.75% of 3-pyridylcarbinol 
or niceritrol in the diet produced a long lasting and significant 
decrease of the plasma cholesterol by about 150 mg/100 ml, 
predominantly by reducing the raised plasma LDL, whereas 
nicotinic acid produced only a transient decrease. Niceritrol 
and 6-pyridylcarbinol markedly reduced the lipid infilterated 
area of the abdominal aorta and the accumulation of free and 
esterified cholesterol in the abdominal aorta and coronary 
arteries, whereas nicotinic acid was less effective in the 
latter respect. Part of the antiatherosclerotic action of 
6-pyridylcarbinol and niceritrol was due to their hypocholest-
erolemic effect. A more direct action on vascular wall was 
probably also involved (Lundholm et al_. , 1978). Both perycit 
and (pyridine 2,5-dicarboxylic acid) di 6-pyridylcarbinol 
ester (S-2042) in a dietary concentration of 0.5% decreased 
cholesterol. This reduction, as well as that induced by 
vitamins was confined to VLDL fraction. Only S-2042 slightly 
reduced the cholesterol accumulation in the aorta of athero-
sclerotic rabbits (Brattsand, 1975b) . 
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Ethyl p-chlorophenoxyisobutyrate and Derivatives; The acceptance 
of this drug is based on its ability to reduce levels of both 
cholesterol and triglycerides (reflecting effects upon LDL and 
VLDL respectively) and upon its low order of toxicity. Ethyl 
p-chlorophenoxyisobutyrate (CPIB) is a branched fatty acid 
ester that can effect a wide range of metabolic activities of 
lipids and lipoproteins. These include reduced cholesterol 
synthesis (Thorp and Waring, 1962), interference with lipo-
protein synthesis (Gould et_ al^ . , 1967), inhibition of fatty 
acid synthesis (Maragoudakis, 1969), stimulation of lipo-
protein lipase activity in adipose tissue (Tolman et^  al.-/ 19 70), 
stimulation of adenyl cyclase activity (Greene et. a]^., 1970), 
and lowering of basal glycerol release from epididymal fat 
(Carlson et_ al_., 1972). Investigations on lipemic rats 
(Segal et_ al_. , 1972) and lipemic man (Wolfe et_ al^ . , 1973) 
have demonstrated improved removal of triglycerides from the 
plasma as a major response. However, in normal rats (Adams 
et al^ ., 19 71; Cenedella and Crouthamel, 19 76) and man 
(Wolfe et a2., 1973; Zakim and Herman 1969), not only enhanced 
removal of triglycerides is obvious, but also very little 
reduction in plasma triglyceride concentration is observed. 
In fact, reduction in hepatic triglyceride has been noted in 
normal rats without enhanced removal (Adams et_ al^ . , 1971; 
Cenedella and Crouthamel, 19 76). Evaluation of both production 
and removal of plasma triglycerides in nonual and hyper-
lipemic rats, provide evidence that predominant lipid reducing 
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action of clofibrate is manifested in the hyperlipemia state, 
and predominently upon peripheral lipid disposal without 
altering triglyceride production (Simonelli and Eaton, 1978) . 
CPIB inhibits cholesterol synthesis between acetate and 
mevalonate. It prevents the formation of fatty liver induced 
by orotic acid suggesting that the effect is mediated through 
a 3-lipoprotein response (Westerfeld et_ al_., 1972). Although 
earlier reports indicated that hypolipidemic action of CPIB is 
dependent upon the nature and type of diet (Zakim and Herman, 
1969; Kokatnur and Malcom, 1970a; 1970b). It has been recent-
ly reported that the hypolipidemic action of CPIB is independent 
of the type of dietary fat in diet (Saito, 1975). Cayen (1975) 
found that CPIB lowered the elevated seriom lipid levels in 
experimentally induced diabetic rats. 
Various clofibrate analogues have been described as 
hypocholesterolemic and hypolipidemic agents in the treatment 
of atherosclerosis. A new derivative tetralylphenoxyisobutyrate 
(TPIA or SU-13437) was found effective in reducing serum tri-
glyceride and cholesterol levels in Type III, IV and V hyper-
lipoproteinemia. Type II patients responded to a lesser 
degree (Hartman and Forster, 1969). According to Best and 
Duncan (1970) TPIA is more potent than clofibrate. However, 
a decrease of fibrinolytic activity was observed during the 
treatment with TPIA (Mannucci et_ al_., 19 71). Another analogue 
of CPIB, l-methyl-4-piperidyl bis(p-chlorophenoxy) acetate 
(SaH 42-348) was found more effective in reducing serum 
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triglycerides and cholesterol than CPIB (Barkowitz, 1969; 
Timms et_ al_., 1969). Halofenate, structurally related to 
clofibrate is a hypolipidemic and hypouricemic drug. In two 
short term clinical trials, it lowered the serum lipid levels 
of patients with hyperlipidemia (Sirtori et_ al_. , 1972). 
Newman et^  al^ . (197 3) reported the hypolipidemic properties 
of certain acyclic and cyclic analogues of CPIB for Triton 
WR-1339 induced hyperlipidemic rats. The cyclic analogues 
include 1,4-benzodioxane and ethyl 6-chlorochroman-2-carboxymate, 
t"Jhen CPIB and andostrone (Atromid S) are administered simul-
taneously, prolongation of the thrombin time, decrease of 
platelet adhesiveness, and increased fibrinolytic activity 
was observed. It has no influence on known components of the 
fibrinolytic system, when given alone (Sweet ejt al^ . , 1965). 
CPIB has been associated with relatively overt side effects. 
It can occasionally cause nausia, diarrhoea and weight gain, 
but these usually disappeard quickly. Rare side effects in-
clude skin rash, weakness, giddiness and vomitting. 
2. Drug Combinations 
Until recently plasma lipid lowering drugs were used 
as single drug treatment, most often in combination with some 
dietary advice, but in recent years interesting reports on 
drug combinations have emerged. There are three reasons for 
combining two or more different plasma lipid lowering 
compounds. 
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(i) Treatment with one drug at its maximal dose 
does not always correct hyperlipoproteinemia. 
This is often the case in homozygous or pro-
nounced heterozygous Type II A and in excessive 
Type IV. 
(ii) The rate of occurrance of CHD is positively 
related to plasma triglyceride or cholesterol 
levels not only in hyperlipoproteinemia but 
also within the wide 'normal range'. There-
fore, it seems logical to aim at maximal 
decrease of VLDL and LDL in order to prevent 
or delay CHD. 
(iii) Some drugs show unwanted reciprocal lipoprotein 
effects. For example, treatment with clofibrate 
may increase LDL concentration in patients with 
low LDL Type IV pattern and treatment with bile 
acid sequestrants may result in increase in VLDL 
fractions in subjects with Type II A. Combina-
tion of drugs may eliminate these drawbacks. 
Nicotinic Acid Derivatives plus Clofibrate: The effect of a 
combination of nicotinic acid derivative, pentaerythritol 
nicotinate, Perycit and clofibrate (Atromidin) was studied by 
Olsson et aJ^ . (1975) . Since the standard dose of clofibrate 
is often not sufficient to noiniialize serun lipids, particularly 
in the treatment of serum cholesterol elevations, the effect 
of a combination with nicotinic acid was studied. It was 
found in this study that the combination of clofibrate and 
niceritrol had a pronounced effect on sertom lipids and lipo-
protein in 29 patients with Type II A and II B hyperlipo-
proteinemia. Niceritrol alone did not lower the serum 
triglyceride concentrations in Type II A with any dose. The 
combination of the two drugs reduced triglyceride concentra-
tions by 30% and serum cholesterol by 22%. Combined treat-
ment with 2 gm CPIB and 3 gm niceritrol resulted in a normal 
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lipoprotein pattern in 15 out of 17 subjects. No additional 
side effects were observed during combined treatment. 
In an ongoing study by Carlson ejt al_. , (1977), five 
hundred and fifty eight consecutive survivors of myocardial 
infarction below 70 years (mean age 59 years) were randomly 
allocated into a control group and a chemotherapy group from 
December 1972 to April 1976. The chemotherapy group was 
prescribed clofibrate 1 gm twice daily, and nicotinic acid 
1 gm three times daily. Serum cholesterol and triglycerides 
were lowered 15-20%, and 30% respectively in the chemotherapy 
group while only insignificant reductions were observed in 
the control group. Until December 1976, total mortality and 
mortality from ischemic heart disease had been the same in the two 
groups. The niimber of non-fatal myocardial infarction had 
been 38 in the control and 19 in the chemotherapy group, a 
statistically significant reduction. 
In another study by Graham et a]^., (1977), forty-eight 
patients under 65 years were included in a double-blind study 
for comparison of the lipid lowering effect of clofibrate with 
that of 3-pyridylcarbinol combined with clofibrate. Over 
four months there was no significant difference in the lipid 
lowering effect of either regime. A mean reduction of tri-
glyceride of approximately 30% and of cholesterol of 18% was 
observed. Both the drugs caused significantly greater reduc-
tions than placebo. 
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Bile Acid Sequestrants plus Clofibrate: Howard and Hyams 
(1971) reported a good synergistic effect of the combination 
of PDX chloride (Secholex or DEAE-Sephadex) and clofibrate 
resulting in a total plasma cholesterol decrease of 34% after 
two weeks' treatment. In another study (Oliver, 1974) 16 gm 
cholestyramine (Questran) daily or 15 gm PDX chloride daily 
in combination with 2 gm clofibrate (Atromidin) for two 
months reduced the concentration of plasma cholesterol in 
Type II A hyperlipoproteinemic subjects. For cholestyramine 
plus clofibrate, the total plasma cholesterol decrease 
amounted 30% and the corresponding figure for PDX chloride 
was 24%. Comparing the effect of bile acid sequestrants 
alone, it seems that the addition of clofibrate has a marked 
effect in the PDX chloride treated group, thus compensating 
for the relatively poor effect of PDX alone. 
Colestipol plus clofebrate: Recently Fellin et_ a_l. (1978) 
evaluated the effect of the association of cholestipol with 
clofibrate in the long-term treatment of familial hyper-
cholesterolemia. Twenty subjects (12 Type II and 8 Type II B); 
previously treated with cholestipol for 16 months, were 
subjected to therapy with cholestipol (ISqn/day) plus clofibrate 
(2 gm/day) for 15 months. In Type II A patients, the combina-
tion of these drugs enhanced the decrease in plasma cholesterol 
levels. In Type II B patients, on the other hand, the combina-
tion of clofibrate with cholestipol induced an increase in 
plasma cholesterol levels. A markedly significant decrease 
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in plasma triglyceride levels was observed in this group 
suggesting that, in Type II A, clofibrate enhances the 
resin's hypocholesterolemic effect. This is in agreement with 
the earlier findings (Goodman et^  al_., 1973; Howard and Evans, 
1974). In Type II B, on the other hand, the combination of 
these drugs did not seem to be indicated since a marked 
hypotriglyceridemic effect was accompanied by an increase in 
plasma cholesterol levels. 
Nicotinic Acid plus Cholestyramine: Moutafis et_ al^ . (1971) 
showed that oral administration of cholestyramine with nicotinic 
acid decreased serum cholesterol in patients with familial 
hyperlipoproteinemia. Out of four subjects only one had a 
sustained reduction in serum cholesterol. They suggested that 
a combination of cholestyramine and nicotinic acid decreases 
the mass of exchangeable cholesterol in the body by increasing 
cholesterol removal and inhibiting the compensatory increase 
in hepatic cholesterol synthesis, that would otherwise occur 
in response to increased removal. The reports of another 
study indicate that the combination of nicotinic acid with a 
bile acid-binding resin may be a more effective approach to 
these subjects. In the study, five of six such patients had 
a sustained reduction in serum cholesterol of 33% below the 
level achieved with resin alone (Levy et al., 1972). 
C H A P T E R II 
M A T E R I A L S A N D M E T H O D S 
A . iMATERIALS 
1. Animals 
Unless mentioned otherwise, adult male albino rats 
used in the present study were purchased from the stock colony 
of a local animal supplier. White Leghorn chickens were 
purchased from Vijay Poultry Farm, Aligarh (India). 
2. Experimental Manipulations 
The animals were conditioned for 2-3 weeks on basal 
diet prior to their transfer on experimental diet. For pro-
ducing hyperlipidemic conditions, the animals were kept either 
on hypercholesterolemic diet or treated as described below. 
The diet and water were given ad_ libitum. The animals were 
always randomly divided into groups as indicated in Chapter III, 
Basal Diet: Hind Lever Rat Feed and Hind Lever 
Poultry Feed was obtained from Hindustan Lever Ltd., India. 
Cholesterolemic Diet: The following ingredients were 
mixed as w/w percentage (Fujiwara et al., 1972): casein 15; 
sucrose 67.1; hydrogenated vegetable oil 10; salt mixture^ 4; 
cellulose 2; vitamin mixture 0.5; chloride 0.2; cholesterol 1, 
and cholic acid 0.2. 
^The salt mixture contained (percent in the mixture): 
NaCl 4.6; Na^HPO..H^O 9.3; K-HPO. 25.6; CaH(PO.)2•H^O 14.5; 
-Fe (C6H507)5H20 3.2; Ca(C3H5O3)5H2O 34.9; MgSO^ 7.0; KI 0.9. 
One hundred gm of the vitamin mixture contained (in mg): 
riboflavin 150; thiamin 100; nicotinic acid 1000; pyridoxine 100; 
cyanocobalamine 1; pantothenic acid 500; folic acid 50; ascorbic 
acid 3750; vitamin E 100; Vitamin A 250,000 I.U.; Vitamin D2 
20,000 I.U. and sucrose to 100 gm 
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Intubation of Olive oil; To induce hypertriglyceridemia, 
the animals were loaded orally with olive oil at the dose of 
20 ml/kg, (Duhault et_ al_. , 1976) 2 hour after drug administra-
tion. 
Alloxan treatment; Diabetes was induced in rats by 
a single subcutaneous injection of 180 mg alloxan per Kg 
body weight. The rats were fasted for 48 hr before alloxan 
administration. Insulin injection i.p. 0.5 unit/130 gm body 
weight, was adjusted daily for glucosuria ++ or +++ (test 
tape) and stopped 18 hr before sacrifice (Malathy and Kurup, 
1972) . 
Carbon tetrachloride treatment: The animals kept on 
basal diet were given intramuscular injections of carbon-
tetrachloride at the dose of 3 ml/kg per day (l:lv/v) in 
mineral oil. In 48 hr study, the injections were given at 
intervals of 0, 6, 24 and 30 hours. They received an in-
jection every day in 168 hr study (Vaishwanar et_ a]^. , 1972). 
Cobalt Chloride treatment: To produce hyperlipidemic 
conditions, the animals were given intramuscular injections 
of cobalt chloride at a dose level of 25 mg/kg/day for seven 
days (Morita et^  al., 19 74). 
Triton Treatment: Chickens conditioned on basal 
diet received i.p. injection of 300 mg Triton WR-1339/kg 
body weight dissolved in 0.15 M sodiLmi chloride (Schurr ejt al., 
1972) . 
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3. Sacrifice 
To avoid possible differences due to diurnal rythm, 
all the animals, except in carbon tetrachloride and olive oil 
treatment, were sacrificed around 10.00 A.M. The animals 
fasted overnight were anesthetized with ether, blood with-
drawn by cardiac puncture (allowed to coagulate before serum 
was separated by centrifugation), excised, tissue(s) removed, 
quickly washed, blotted, weighed and suspended in a mixture 
of chloroform-methenol (2:1, v/v) for lipid extraction as 
described later. 
4. Chemicals 
Spec ia l r e a g e n t s o b t a i n e d from commercial sou rces and 
used wi thou t f u r t h e r p u r i f i c a t i o n s i n c l u d e d : 3-Hydroxy-3-
m e t h y l g l u t a r i c ac id (Schwarz/Mann, U . S . A . ) ; Nicotinic acid (Nutri-
t ional Biocheinicals, U.S.A.); l-ainino-2-hydroxynaEdithalene-4-sulphonic acid 
(sodium s a l t ) ; cholic acid and choline chloride (L. Merck, Germany) ; 
t r i c h l o r o a c e t i c ac id and p e r c h l o r i c a c i d 70% (Riede l , Germany); 
c h o l e s t e r o l ( J . T . Baker Chemical Co . , U . S . A . ) ; hydrogenated 
v e g e t a b l e o i l (Trade name 'DALDA' of Hindustan Lever L t d . , 
I n d i a ) ; o l i v e o i l ( B e r t o l l i , I t a l y ) ; Zeocarb-225 (Ion-Ex-
change L t d . , I n d i a ) ; T r i t o n WR-1339 ( g i f t from Upjohn Co. 
L td . , U . S . A . ) ; Al loxan and c o b a l t c h l o r i d e (B.D.H., I n d i a ) , 
cycloheximide (Sigma Chemical Co . , U . S . A . ) . Rest of t h e 
chemicals and s o l v e n t s were of r eagen t g r a d e , g l a s s d i s t i l l e d 
water was used th roughout the s t u d y . 
•*± 
B. CHEMICAL METHODS 
1. Extraction of Tissue Lipids: 
Tissues were extracted for total lipids by the 
method of Folch et. al_. (1957). A known weight (0.3 - 1 gm) 
of tissue randomly selected, and cut from the tissue was 
grinded using pestle and mortar with 20 fold (w/v) chloroform-
methanol (2:1, v/v) mixture. The homogenate was filtered 
through Whatman No. 1 filter paper into a glass stoppered tube. 
A suitable aliquot (6-10 ml) of this tissue extract was trans-
ferred to another glass stoppered tube. This crude extract 
was mixed thoroughly with 2 ml of 0.9% sodium chloride, and 
was allowed to stand for 5-6 hr till two phases without inter-
facial fluff separated. The upper aqueous phase was removed 
as much as possible by a syringe. The lower phase was gently 
washed 3 times with known amount of the salt solution by 
slowly adding it along the side of the tube by a swirling 
action of the pipette. This was done to avoid disturbance 
of the lower phase. Finally, the lower phase, without dis-
turbing the remaining rising fluid, was made into one phase 
by addition of methanol (10-15 drops). The resulting solu-
tion was diluted to 10 ml in a standard flask by addition of 
chloroform-methanol mixture (2:1, v/v). This solution was 
then used for various lipid estimations. 
2. Quantitative Determination of Total Cholesterol 
The method used was essentially that of Zlatkis et al. 
(1953). A suitable volume of serum of lipid extract (0.05 to 
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0.5 ml) was added to 3 ml glacial acetic acid and mixed 
thoroughly. Two ml of ferric chloride reagent (freshly pre-
pared by diluting 1 ml of 10% w/v, ferric chloride in glacial 
acetic acid to 100 ml with concentrated sulphuric acid) was 
carefully added from the side to allow the formation of a 
brown ring. The tubes were shaken thoroughly, cooled and 
colour density read in a Baush and Lomb 'Spectronic 20' 
spectrophotometer at 560 nm against a reagent blank. A 
cholesterol solution of known strength prepared in glacial 
acetic acid was used to prepare a standard curve. Under 
described experimental conditions, an optical density of 
1.00 was equivalent to 232 ug cholesterol. 
3. Quantitative Determination of Triglycerides 
Total triglycerides were determined by the method of 
Van Handel and Zilversmit (1957). Four gm of zeocarb-225 
placed in a glass stoppered 100 ml conical flask and was 
moistened with 2 ml chloroform. After adding a suitable 
aliquot (0.03-1 ml) or seriim of lipid extract of tissue, 
10-15 ml chloroform was added. The contents allowed to stand 
for 1 hour at room temperature (intermittent shaking was 
done), were filtered through a l^ Thatman No. 1 filter paper, 
2-3 ml aliquot of filtrate was transferred to three glass 
stoppered tubes and solvent evaporated. To two tubes 0.5 ml 
of 0.4% alcoholic potassium hydroxide (w/v) was added, but 
only 0.5 ml of alcohol was added to the third tubes (un-
saponified sample). All the tubes were kept at 60-70° for 
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15 minutes. 0.5 ml of 0.2 M sulphuric acid was added to 
each tube, which was placed in a gently boiling water-bath 
for 15 minutes to remove alcohol. After cooling the tri-
glyceride content was determined by periodate oxidation. 
0.1 ml of 0.05 M sodiiom periodate solution was added to the 
tubes and oxidation was stopped exactly after 10 minutes by 
the addition of 0.1 ml of 0.5 M sodium arsenite. A yellow 
colour of iodine appeared which disappeared within few minutes. 
Nine ml of 0.24% chromotropic acid reagent (in sulphuric 
acid and water 2:1, v/v) was added and heated for exactly 30 
minutes in boiling water bath. The colour was read in Baush 
and Lomb 'Spectronic 20' spectrophotometer at 570 nm. The 
quantity of triglyceride is represented in terms of weight of 
corn oil which has been used as standard for triglyceride 
estimation. One optical density unit was equal to 188 ug 
corn oil equivalent triglycerides. 
4. Quantitative Determination of Total Phospholipids 
Total phospholipids were determined by the method of 
Bartlett (1959) as modified by Marinetti (1962) . For direct 
determination from serum, 0.01-0.1 ml sample was delivered 
into centrifuge tubes containing 0.5 ml of water. Three ml 
of freshly prepared 10% (w/v) trichloroacetic acid solution 
was added. The tubes were allowed to stand for few minutes 
and centrifuged at 3000 r.p.m. for 15 minutes. The super-
natant was decanted and tubes inverted on filter paper until 
practically all the supernatant was removed. For total 
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phospholipid determination from tissue lipid extract, a 
suitable aliquot (0.05-0.1 ml) was taken into a tube and 
evaporated to dryness. The contents of tubes were digested on 
an electric digestion unit with 1 ml perchloric acid (70%) 
for 15-20 minutes (2-3 glass beads of boiling chips were added 
in each tube to avoid bumping). On cooling, 7 ml distilled 
water was added followed by 1.5 ml of 2.5% (w/v) ammonium 
molybdate. The tubes were shaken thoroughly and 0.2 ml of 
0.25% (w/v) l-amino-2-hydroxynaphthalene-4-sulphonic acid was 
added. The tubes were heated in boiling water-bath for 
exactly 7 minutes, cooled and colour read after 20 minutes in 
Baush and Lomb 'Spectronic 20' spectrophotometer at 830 nm 
against a reagent blank. For a calibration curve monopotassium 
dihydrogen phosphate was used as standard. It was found that 
an optical density of 1.00 was equivalent to 10 ug phosphorus. 
The phospholipid values were obtained after multiplying the 
phospholipid phosphorus by a factor of 25. 
5. Quantitative Determination of Blood Glucose 
Serum glucose was determined by the method of Nelson 
(1944). 0.1 ml of serum was delivered into centrifuge tube 
containing 1.5 ml of water. 0.2 ml of 0.3 N barium hydroxide 
solution was added to the mixture followed by 0.2 ml of 5% 
solution of ZnS0..7H^0, with thorough shaking. The tubes 
were allowed to stand for several minutes and then centrifuged 
at 3000 r.p.m.for 15 min. One ml of supernatent was then 
pipetted into a test tube graduated at 25 ml for further 
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analysis. One ml of alkaline copper reagent prepared on the 
same day by mixing 25 parts of copper reagent A*to 1 part of 
B** was added. The solutions were mixed and heated in a boiling 
water bath for 20 minutes. After cooling, 1 ml of arsenomo-
lybdate reagent (containing 25 gm of ammonium molybdate in 
450 ml water, 21 ml concentrated H2SO. and 3 gms Na_HASO. 
dissolved in 25 ml of water) was added. The reaction mixture 
was allowed to stand for a few minutes until the effervescene 
ceased. The samples were mixed thoroughly and diluted to 25 
ml upto the mark. A stable blue colour quickly appeared which 
was read in Bausch and Lomb 'Spectronic 20' spectrophotometer 
at 600 nm against a reagent blank. A glucose solution of 
known strength was used to prepare a standard curve. Under 
described experimental conditions optical density of 1.00 
was equivalent to 233 yg glucose. 
6. Quantitative Determination of Free Fatty Acids 
The free fatty acids in serum were estimated by the 
method of Koichi and Michio (1965) . To a centrifuge tube 
containing 3 ml chloroform, was added 0.2 to 0.3 ml serum. 
The solution was shaken thouroughly and then centrifuged at 
3,000 rpm for 10 minutes. The upper layer containing the 
protein precipitate was removed with the help of a syringe. 
1.5 ml of chloroform layer was then pippeted into a glass 
*Reagen t A: 
25 gm Na-CO^ + 25 gm Sodium potassium t a r t a r a t e ^ 20 mg NaHCOo 
2 00 gm Na„SO (Anhydrous) i n 80 0 ml of w a t e r and d i l u t i n g t o 
1000 m l . ^ ^ 
* * R e a g e n t B! 
15% CuS0^ .5h20 c o n t a i n i n g 1 t o 2 d r o p s of H2SO. 
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stoppered tube containing 4.5 ml chloroform. To this was 
added 3 ml of copper-triethenolamine solution (prepared by 
mixing 1 M triethenolamine,1 N acetic acid and 6.45% CuCNO^)^ 
SH-O in the ratio of 9:1:10 v/v). The tubes were shaken 
mechanically for 10 min. After a settling period of 30 min. 
or more the copper-triethenolamine solution was aspirated 
with a syringe. To 4 ml of the chloroform layer, was added 
0.4 ml sodium diethyldithio carbamate (0.1% in n-butanol 
w/v). The yellowish brown colour developed immediately was 
measured in Bausch and Lomb 'Spectronic 20' spectrophotometer 
at 440 nm against a reagent blank. Palmitic acid 
solution of known strength was used to prepare a standard 
curve. One optical density unit was found to be equivalent 
to 134.4 ug palmitic acid. 
7. Treatment of Data 
Unless mentioned otherwise, per cent reduction in 
tissue lipids was calculated in the following manner: 
Per cent _ Value of control.group - Value of HMG treated group ,„Q 
Reduction ,, , ^ , , 
Value of control group 
All determinations were done in a t l e a s t d u p l i c a t e s . 
S t a t i s t i c a l s igni f icance was ca lcu la ted by S tuden t ' s t - t e s t . 
C H A P T E R I I I 
R E S U L T S 
RESULTS 
1. Dose Response Effect of Single and Combined HMG and 
Nicotinic Acid treatment on Various Tissue Lipids in 
Hyperlipidemic Rats 
Seven groups, each of five rats, weighing about 100-
150 gm were fed a high cholesterol diet as described in 
chapter II. Along with the diet the animals received each 
day i-p. HMG at the concentration of 10 and 20 mg/kg body 
weight in 1 ml saline. Two doses of nicotinic acid, 40 and 
80 mg/kg in 1 ml saline were administered i.p. to two other 
groups. The rest two groups received a combination of 10 mg 
HMG plus 40 mg nicotinic acid, and 20 mg HMG plus 80 mg 
nicotinic acid/kg in 1 ml saline. The hyperlipidemic control 
group received i.p. 1 ml saline only. After two weeks of 
treatment, the animals were sacrificed. Various lipid para-
meters were determined in seriim, liver and aorta (Table 2) . 
HMG Dose-Response Study: 
As evident from Table 2, i.p. administration of HMG 
at a dose of 10 mg/kg significantly decreased serum trigly-
cerides to the extent of 28%. The triglyceride levels in 
liver and aorta were, however almost not affected. An 
insignificant reduction was observed in cholesterol in serum, 
liver and aorta. HMG treatment at a dose of 20 mg/kg 
significantly lowered cholesterol to the extent of 40%, 18% 
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and 35% and triglycerides to the extent of 49%, 24% and 22% 
respectively in seriim, liver and aorta. The effect of HMG on 
cholesterol and tryglyceride levels were dose-related. 
Nicotinic Acid Dose-Response Study: 
We have confirmed the earlier findings of Olsson et al. 
(1975) that nicotinic acid has a dose-response effect on both 
serum cholesterol and triglycerides. Nicotinic acid at a dose 
of 40 mg/kg significantly reduced cholesterol and triglyceride 
levels in serum to the extent of 20% and 42% respectively, 
whereas, these lipid parameters in liver and aorta were in-
significantly decreased. The higher dose of nicotinic acid 
i.e. 80 mg/kg significantly lowered cholesterol in serum, 
liver and aorta to the extent of 39%, 15% and 39% and tri-
glycerides to the extent of 48%, 20% and 22% respectively. 
Combined Effect of HMG and Nicotinic Acid: 
Intraperitoneal treatment of a combination of 10 mg 
HMG and 40 mg nicotinic acid/kg resulted in a significant 
lowering of cholesterol in serum, liver and aorta to the 
extent of 50%, 27% and 28%, and triglycerides to the extent 
of 61%, 13% and 16% respectively. The combined higher dose 
of 20 mg HMG and 80 mg nicotinic acid significantly reduced 
cholesterol in these tissues to the extent of 63%, 35% and 44%, 
and triglycerides to the extent of 69%, 29% and 29%, respect-
ively. The tissue phospholipids were, however, neither 
affected by single doses nor by any combined dose used. 
During the combined treatment, the effect on all lipid 
50 
> 
o 
•H 
0) 
s. 
4-1 
c 
o 
•H 
U 
•H 
-P 
o 
o 
• H 
s 
c 
4-1 
o 
81 
a 
TJ 
(U 
c; 
• H 
XI 
e 0 
u 
TJ 
c 
re 
M 
•P 
(0 
CD Pi 
r-l 
i j i 
fi 
•H 
CO 
m 0 
U 
• H 
g Q) 
Ti 
•H 
a 
• H 
•(-) r H 
o 0 
iJ-l 
4-t 
W 
• 
00 
<U 
i H 
Xi 
(TJ 
El 
U 
Q) 
Cu 
> i 
K 
o -q L2 O -H 
g -H O 
S 2 cC 
Cr 
g ^ o . 
O O -H 3 
CM 00 -P a 
+ 1 
§ •'-' y S Z <u 
tP 
H^g'.^-^ 
O O -H 0) 
iH ' y +J Qj 
lb Ti 
0 -W 
•H U 
Z (0 
tri 
•^§t^  
00 -P a 
ro 
• 
o 
— 
o 
"a* 
• 
o 
+1 
CN 
in 
• "3* 
VD 
• O 
+i 
o 
• 
r-\ 
O 
« O 
V 
d, 
CN 
O 
O 
V 
Ch 
• 
Ui 
• 
2 
S.'S 
-H 
g" 
O 
^ 
Cn 
. ^ ^ 
-5 
4-> 
M a 
0? 
O 
CN 
u 
I 8 en 
o 
CN 
ir, 
ID 
(N 
O 
CO 
in 
^ 
•z 
T T 
• O 
+: 
•^ 
ro 
• 
• 'J ' 
fO 
• 
o 
+, 
V£> 
in 
• 
r-i 
O 
• o 
V 
CU 
CN 
O 
• o 
V 
CU 
^ 
ip 
o 
en 
u 
en 
C 
• H 
'd 
CD 
to 
U) 
0) 
M 
Q-
IX 
0) 
P 
0 
P 
P 
W 
TJ 
P (0 
^ 
c (0 
+J 
in 
+1 
c 
fO 
Q) 
s 
+J 
c fd 
u 
• p 
M-l 
•p 
c 
en 
• P 
w 
• p 
0 
2 
II 
. 
Ui 
• 
2 
51 
parameters in these tissues were more efficient than either 
compound in these doses. The effect on cholesterol level 
was more marked than with either compound alone. Similar 
results were obtained for triglyceride levels in these 
tissues. 
On administration of 10 or 20 mg HMG in rats (Table 3) , 
a significant decrease in average wet weight of liver was 
observed. There was no change in liver weight by the adminis-
tration of either dose of nicotinic acid. Administration of 
combined lower or combined higher doses of the two compounds 
caused a significant reduction of the same magnitude as with 
10 or 20 mg HMG/kg. There was no marked difference in dietary 
intake among control group and treated groups. In all groups 
the animals remained active throughout the experimental 
period. 
Effect of HMG on Olive Oil - Induced Hypertriglyceridemia in 
Rats 
Four groups of rats weighing 120-150 gm were fed basal 
diet and water ad_ libitixm. They were fasted overnight prior 
to the start of experiment. The experiment was performed 
in two sets. HMG at the concentration of 50 mg/kg body 
weight in 1 ml saline was orally administered to the experiment-
al animals in both the sets. Then after two hours, all the 
animals were loaded with olive oil, 20 ml/kg body weight by 
gastric intubation. Two hours later, the rats in the first 
set of two groups of 10 animals were sacrificed. The animals 
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of the second set were sacrificed six hour after HMG administ-
ration. The respective control groups were in two separate 
sets. They received an equal volume of saline in addition 
to olive oil for the same period. Five normal rats of similar 
body weight in basal group were also sacrificed at the same 
time for comparison of lipid values. Triglyceride, phospholipid, 
cholesterol and free fatty acid levels were estimated in serum. 
The data of this experiment confirm the findings of 
Duhault et. al^ . , (1976), that the oral administration of olive 
oil produced hyperlipidemic conditions in rats. The increase 
in triglyceride was more marked as compared to other lipid 
levels. As shown in Table 4, two hour HMG treatment significant-
ly checked the rise in triglyceride, phospholipid and free 
fatty acids by 19%, 26% and 20% respectively. HMG treatment 
for 6 hours was more effective in counteracting hyperlipidemia 
in rats. The HMG-induced lipid lowering was significant to the 
extent of 31% in triglyceride, 16% in cholesterol, 25% in 
phospholipid and 24% in free fatty acid levels. The liver 
weights in both the sets of experiment were unchanged and the 
animals remained active during the experimental period. 
The Protective Effect of HMG in Alloxan-Induced Diabetes in 
Rats 
Male albino rats weighing 100-150 gm were conditioned 
on basal diet prior to the start of the experiment. They were 
made diabetic by a single subcutaneous injection of 180 mg 
alloxan/kg body weight. The rats were fasted for 48 hour 
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before alloxan administration. The alloxan solution was made 
just prior to injection and used as quickly as possible. Urine 
sugar was checked at regular intervals from fifth day. Insulin 
injection i.pi 0.5 unit/130 gm rat, was adjusted daily for 
glucosuria ++ or +++ (test tape) and stopped 18 hour before 
sacrifice. The animals with marked hyperglucosuria were selected 
for experiment and were divided into 2 groups of 5 animals each. 
The animals were sacrificed fifteen days after the alloxan 
injection. From the tenth day onwards the treated animals 
were given i.p. HMG at the concentration of 50mg/kg/day. The 
control group received an equal voliome of saline. On the 
last day blood was withdrawn after an overnight fast. Five 
normal rats were also sacrificed at the same time for compar-
ison. Various lipid paremeters were determined in serum and 
liver. Glucose content of serum was also determined. 
The diabetic state induced in rats with alloxan 
was characterized by increased food intake, hyperglucosuria, 
hyperglycemia and by a decrease in body weight gain and liver 
weight. Diabetic rats had marked increase in cholesterol, 
triglyceride free fatty acid and phospholipid levels in seriom. 
In liver triglycerides and phospholipids increased whereas 
cholesterol decreased. As shown in Table 5, HMG effectively 
protected the diabetogenic action of alloxan by decreasing 
cholesterol, triglyceride, phospholipid and free fatty acids 
in serum by 12%, 36%, 16% and 23% respectively. Hepatic 
cholesterol lowered significantly to the extent of 11%. 
56 
An insignificant reduction was observed in hepatic triglyceride 
and phospholipid levels. The maximiim effect of HMG was observed 
in triglyceride concentrations in serum indicating a beneficial 
effect of HMG. The mean blood glucose values of diabetic 
animals receiving HMG were much smaller than those of the un-
treated diabetic controls. It was interesting to note that 
the physical condition of diabetic rats improved on HMG 
treatment. The liver weight decreased in diabetic animals 
and remained unaltered on treatment with HMG. 
Protective Effect of HMG on Carbon tetrachloride - Induced 
Fatty Liver in Rats 
With slight modification the method used was essential-
ly that of Vaishwanar et al., (1972) . Thirty rats weighing 
110-140 gm were fed basal diet and water ad libitum. In this 
study intra muscular injections of carbon tetrachloride 3 ml/ 
kg/day (1:1 v/v) in mineral oil and 50 mg HM3 /kg dissolved in normal 
saline were used. The effect of HMG on carbon tetrachloride 
treated animals was studied at intervals of 48 and 168 hours. 
In 48 hour study, the rats received simultaneous injections of 
carbon tetrachloride i.m.and HMG i.p,50 mg/kg at an interval 
of 0,6,24 and 30 hours. The control group received similar 
doses of carbon tetrachloride and an equal volume of saline 
at similar intervals. Animals in both the groups were sacrificed 
at the end of 48 hours. The animals were kept fasting during 
the experimental period. In 168 hour study, the treated 
animals received simultaneous injections of carbon tetrachloride 
and HMG daily for seven days. The control group received 
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carbon tetrachloride and saline only. The animals were 
sacrificed one hour after the last treatment. Six normal rats 
of similar body weight were also sacrificed for comparison 
purposes. 
In agreement with the earlier reports, cholesterol, 
triglyceride and phospholipid levels substantially decreased 
in serum in carbon tetrachloride treated rats. Moreover, 
these lipid parameters increased in liver in both the ex-
periments (Vaishwanar et_ al_., 1972). Table 6 presents the 
concentration of various lipid levels in seriim and liver for 
48 hour study. HMG elevated serum cholesterol significantly 
to the extent of 20%. The triglyceride and phospholipid 
levels were, however, insignificantly increased due to HMG 
treatment. In liver, cholesterol and triglyceride levels 
were insignificantly lowered whereas the decrease in phospho-
lipid level was significant. In 168 hour study, as evident 
from Table 7, the protective effect of HMG was even more 
pronounced. Cholesterol, triglyceride and phospholipid levels 
in serum were insignificantly increased by 40%, 30% and 46% 
respectively. Furthermore, HMG significantly prevented the 
rise in all these lipid parameters in liver. The observed 
decrease in liver weight due to HMG administration in carbon 
tetrachloride treated rats was statistically significant. 
The extent of reduction was 21o in 48 hour study and 25% in 
168 hour study. The animals tolerated the treatment relative-
ly well. Their average food consumption and body weight 
60 
remained approximately constant in both control and test 
animals. 
Effect of HMG on Cobalt Chloride - Induced Hyperlipidemia in 
Rats 
Twelve male albino rats (110-140 gm) were maintained 
on basal diet for 2-3 weeks. They were divided into two equal 
groups. The treated animals were given simultaneous injections 
of cobalt chloride i.m.25 mg/kg body weight/day and HMG i.p. 
50 mg/kg in 1 ml saline for seven days. The animals receiving 
cobalt chloride and 1 ml saline served as paired control. For 
comparison of lipid values, six normal rats of similar body 
weight were also sacrificed at the same time. At the end of 
experiment, the animals were fasted overnight before sacrifice. 
Various lipid levels were analysed in serum and liver. 
The data in Table 8 confirm the findings of Morita 
et al. (1974) and Ohmichi (1977) that cobalt chloride pro-
duces hyperlipidemic conditions in animals. Intramuscular 
administration of cobalt chloride at the concentration of 
25 mg/kg/day for seven days resulted in a marked increase in 
cholesterol, triglycerides, phospholipids and free fatty acids 
in serum and liver. HHG treatment significantly counteracts 
the enhanced lipemic response of cobalt chloride in rats. 
The magnitude of lowering in serum was 20% in cholesterol, 
34% in triglycerides, 23% in phospholipids and 25% in free 
fatty acids. The decrease in hepatic cholesterol, tri-
glyceride and phospholipid levels were 18%, 22% and 14% 
respectively. 
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The injections of cobalt chloride were tolerated well 
with no apparent ill effects on the animals. Their eating 
habits remained normal and no difference was found in weight 
gain between control and treated groups. However, an in-
significant decrease was recorded in liver weight in HMG 
treated animals. 
Age-Related Responsiveness of Rats to Hypolipidemic Action 
of HMG 
The hypolipidemic effect of HMG was studied in normo-
cholesterolemic rats at varying stages of life. Four groups, 
each of 10 male albino rats were given free access to basal 
diet and water. The first group contained animals of 2-3; 
the second 5-6; the third 9-10; and the fourth 15-20 months. 
They weighed respectively about 30-50 gm; 80-120 gm; 180-220 
gm; 280-300 gm. Sub-groups consisting of 5 animals from each 
group were injected i.p.50 mg HMG/kg/day in normal saline for 
two weeks. The remaining 5 animals in each group received an 
equal volume of saline and served as paired controls. At the 
end of experiment, the animals fasted overnight were 
anesthetized with ether and blood withdrawn by cardiac puncture 
as described in Chapter II. Various lipid parameters were 
analysed in seriom and liver. 
The data shown in table 9 stimmarize the effect of 
HMG on serum and liver lipids in different age groups. The 
contents of cholesterol, triglyceride and phospholipids varied 
with age in serum as well as in liver. In group I, the i.p. 
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administration of HMG lowered triglycerides significantly to 
the extent of 20% in serum and 24% in liver. The other lipids 
of both tissues were insignificantly reduced. In group II, 
HMG caused a significant fall in triglycerides to the extent 
of 21% in serum and 22% in liver. A significant reduction of 
the magnitude of 18% was also observed in serum phospholipids. 
Serum cholesterol and hepatic cholesterol and phospholipids 
showed a small effect. The animals of group III recorded a 
significant decrease of about 25% in cholesterol and 28% in 
triglycerides in serum. Hepatic triglycerides were also 
significantly lowered to the extent of 35%. Other lipid 
levels showed either none or an insignificant response to 
Hr4G treatment. In group IV, serum cholesterol and triglycerides 
significantly declined respectively by 18% and 28%. Among 
hepatic lipids, only the decrease in triglycerides of about 
30% was significant. Serum and liver phospholipids as well 
as cholesterol in liver were insignificantly lowered. The 
results show that there was a little or no lowering effect 
of HMG on phospholipid levels. The maximiom decrease occured 
in triglycerides in both serum and liver in all the groups. 
The HMG-treated groups did not record any significant decrease 
in liver weight. No change in body weight gain between control 
and HMG-treated groups was observed. 
Effect of HMG on Normocholesterolemic chickens 
To evaluate the hypolipidemic action of HMG in normal 
birds, two groups each of 5 white chickens weighing about 
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Table 10. Effect of HMG on Serum Lipids of Normocholesterolemic 
Chickens 
Serum Lipids 
(it^ /100 ml) 
Cholesterol 
Triglycerides 
Phospholipids 
Free Fatty Acids 
Control 
group 
128.5 ± 12.9 
138.0 ± 7.9 
295.0 ± 16.2 
14.1 ± 1.5 
HMG-treated 
group 
94.4 ± 10.0^ 
92.1 ± 8.8 
266.7 ± 14.7 
12.1 ± 1.4 
Per cent 
Redaction 
27 
33 
10 
14 
p-value 
p < 0.05 
p < 0.001 
N.S.^ 
N.S. 
^Mean ± Standard error expressed in mg/100 ml serum for five 
chickens 
N.S. = Not significant 
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700-800 gm were caged separately. They were fed basal diet 
and water ad libitum. While the birds in the HMG-treated 
group were given by gastric intubation 50 mg HMG/kg/day, those 
in the control group received 2 ml saline only. The treatment 
was continued daily for one week. At the end of experiment, 
the animals were fasted overnight and blood withdrawn from 
arm vein for analysis. Various lipid parameters were deter-
mined in serum. 
Data presented in table 10 shows that the oral adminis-
tration of HMG for one week in chickens significantly lowered 
cholesterol and triglycerides levels in serum to the extent 
of 27% and 33% respectively. However, KMG had no significant 
effects on the levels of phospholipids and free fatty acids. 
These findings are in agreement with earlier observations in 
normal rats and rabbits (Yousafzai and Siddigi, 19 76; Umar and 
Siddigi, 1976). The results indicate that HMG has marked hypo-
triglyceridemic action in chickens also. The body weights of 
treated birds were identical to the controls. 
Effect of HMG on Serum Lipids of Chickens treated with 
Triton VJR-1339 
Ten chickens weighing about 700-800 gm were divided 
into two equal groups. They were conditioned on basal diet 
for two weeks and were fasted for 2 4 hr prior to the start of 
the experiment. At the end of 24 hr, all the animals received 
i.v. Triton WR-1339 at a dose of 300 mg/kg body weight 
dissolved in 0.15 M NaCl. The experimental animals were given 
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in addition HMG i.p.at the concentration of 50 mg/kg. Each 
animal of the treated group received two doses of HMG, first 
immediately after Triton injection and the second 20 hr later. 
Animals receiving an equal volume of saline i.p.served as 
controls. Blood was withdrawn 20 hr after Triton administra-
tion. Subsequently the animals received second dose of HMG. 
Blood was withdrawn again 43 hr post-Triton period. Fasting 
was continued till the end of the experiment. Various lipid 
contents were analysed in serum. 
The data in Table 11 is similar to the findings of 
Schurr (1972) that the administration of Triton produces 
hyperlipidemic conditions. The lipid levels of HMG-administered 
birds were significantly lower in both durations when compared 
with controls. Cholesterol, triglyceride and phospholipid 
respectively decreased by 38%, 32% and 20% in 20 hr and 35%, 
26% and 25% in 43 hr. Also, an insignificant effect was 
observed in free fatty acids in both sets of experiment. 
However, there was no major difference in the extent of low-
ering in these lipid parameters at 20 hr and 43 hr. 
C H A P T E R IV 
D I S C U S S I O N 
DISCUSSION 
In recent years advances in the study of normal and 
abnormal lipid metabolism have resulted in a broader under-
standing of the mechanism and effect of hypolipidemic drugs 
(Fredrickson and Levy, 19 72). A clear concept of how lipid 
is transported in blood has helped to clarify the etiology 
of lipid disorders, which in turn has provided fresh insights 
into reasons for the efficacy of lipid lowering agents. Thus, 
the management of hyperlipidemia has become increasingly 
precise and the selection of therapy more rational. The 
relationship between elevated serum lipid levels and the risk 
of developing CHD is well established. Because of the corre-
lation of heart disease with elevated serum cholesterol levels, 
most attempts at dietary intervention have centered upon 
limitation of dietary fat in general and saturated fat and 
cholesterol in particular. The hyperlipidemia in relation to 
atherosclerosis is associated with increase in lipoprotein 
concentration (Jones, 1973). Hyperlipidemia and hyper-
lipoproteinemia could be either due to increased release of 
VLDL from liver into plasma or the mechanism of its removal 
from plasma becomes defective. It is known that increased 
fatty acid and cholesterol biosynthesis can lead to elevate 
plasma lipoproteins in man and animals- Genetically obese 
animals that have high lipogenic capacity are also hyperlipidemic 
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(Maragoudakis et_ al^ ., 1972). HMG has been shown to act as an 
inhibitor of cholesterol biosynthesis between HMG-CoA and 
mevalonate (Rabinowitz and Gurin, 1954) and competitively 
inhibits the HMG-CoA reductase (Fimognari and Rodwell, 1965) . 
Beg and Lupien (1972) have shown that it inhibits cholesterol 
biosynthesis. Either oral feeding or more effectively i.p. 
administration of HMG has been shown to exhibit hypocholesterol-
emic and hypolipidemic properties in rats (Beg and Siddigi, 19 6' 
1968) and rabbits (Lupien et^  aJ^ . , 1973a; Yusufi and Siddiqi, 
1974). HMG has been shown to be effective in the treatment 
of 3 patients suffering from Type II hyperlipoproteinemia 
(Lupien et^  a^. , 1973b). It has also been implicated in the 
physiological control mechanism for cholesterol biosynthesis 
(Saleemuddin and Siddiqi, 1973). Oral administration of 1 
gm HMG before the ingestion of whiskey and a fatty meal 
markedly reduce the elevation of serum triglycerides, 3-
lipoproteins, phospholipids and cholesterol in man. In rats 
receiving ethanol and corn oil mixture, HMG also inhibited 
the increase in post-prandial serum and liver lipids 
(Yousufzai et al_., 1976). In rats, HMG effectively counter-
acts the lipemic and atherosclerotic response of massive 
doses of vitamin D-. It regressed the formation of atheromatous 
arterial lesions. Furthermore, the significant decrease in 
serum 3-lipoprotein levels on HMG treatment could be due to 
decrease in VLDL triglyceride and cholesterol levels (Yousufzai 
and Siddiqi, 1976a). HMG significantly decreased cholesterol. 
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triglyceride and phospholipid levels in whole serum, serum 
3-lipoproteins and liver of Triton-induced hyperlipidemic 
rats. They also observed that 50 mg HMG/kg was equivalent to 
20 0 mg nicotinic acid/kg in offering almost total protection 
against lipemic response of either Triton or alcohol in rats. 
It was suggested that HMG exerted its hypolipidemic effect 
through the inhibition of lipoprotein synthesis (Yousufzai 
and Siddiqi, 1976a, 1976b). HMG showed a significant 
cholesterol and triglyceride - lowering effect in the whole 
serum, seriim 3-lipoproteins and liver of rats on all type 
of dietary carbohydrates. The effect was more marked in 
glucose, fructose, sucrose and lactose. The HMG-induced low-
ering of lipid parameters in serirni 3-lipoproteins and also in 
liver could be either due to inhibition of VLDL synthesis or 
to VLDL triglycerides release in liver (Yousufzai and Siddiqi, 
1977a). Simultaneous administration of HMG for 4 weeks to 
rats fed 20% saturated fats prevented the rise of serum 
cholesterol, triglycerides and phospholipids, and cholesterol 
and phospholipids in liver, aorta and heart. HMG significant-
ly lowered the phospholipids in epididymal fat and brain and 
triglyceride levels in seriim, liver and aorta. The maximtom 
hypolipidemic effect was observed in serum (Yousufzai and 
Siddiqi, 1977b). 
Although a large number of compounds have been found 
to lower serum cholesterol and triglycerides in man, the drugs 
used at present are few:clofibrate, nicotinic acid and 
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cholestyramine. Many patients treated for hyperlipoproteinemia 
still have elevated serum lipid values on diet and during 
treatment with the recommended doses of the drugs. 
From the preceding paragraph, it is clear that HMG 
is quite efficient in normalizing tissue lipid levels. The 
purpose of our study was to throw more light on the hypolipi-
demic action of HMG in order to understand its possible mode 
of hypolipidemic action. To obtain sufficient lipid lowering 
response, a combination with nicotinic acid was also studied. 
As evident from Table 2, the administration of 10 mg HMG and 
40 mg nicotinic acid/kg significantly reduced serum triglyce-
ride levels. Except serxom triglycerides, the decrease in all 
the lipid parameters of serxom, liver and aorta was in-
significant, whereas the administration of 20 mg HMG or 80 mg 
nicotinic acid/kg resulted in a significant decrease in 
cholesterol and triglyceride concentrations in all these 
tissues. The combined lower dose of the two compounds 
significantly decreased all lipid parameters in all these 
tissues. The reduction was remarkedly significant on the 
administration of combined higher doses of the two compounds. 
These findings suggest that the reduction in tissue cholesterol 
and triglyceride concentrations by HMG were dose-dependent. 
We confirm the earlier findings of Berge et^  al^ . (1961) ; 
Oro (1970) and Olsson et_ al. (1975) that the hypolipidemic 
effect of nicotinic acid is dose-dependent. We find that 
during the combined treatment, the reduction in all lipid 
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parameters in serum, liver and aorta was more marked than with 
either compound alone in these doses. The effect in cholesterol 
level was more efficient than with either compound alone. 
Similar results were obtained for triglycerides in these 
tissues. The effect observed was, therefore, synergistic. 
On administration of 10 or 20 mg HMG/kg in rats, a significant 
decrease in average wet weight of liver was observed (Table 3). 
There was no change in liver weight by the administration of 
either dose of nicotinic acid. On administration of combined 
lower or higher doses of compounds, a significant reduction 
of the same magnitude as with 10 or 20 mg HMG/kg was observed. 
It is concluded, therefore, that the decrease of liver weight 
in the combined doses in only due to HMG administration and 
not due to nicotinic acid. We confirm the earlier findings 
of Lupien et_ a^. (1973a); Yusufi and Siddiqi (1974); Yousufzai 
and Siddiqi (1977a, 1977b) that HMG lowers the average liver 
weight in rats and rabbits than their respective control 
groups. It is known that in the coronary diseased group, 
both cholesterol and phospholipids are increased in seriom and 
cholesterolrphospholipid - (C/P) ratio was likewise increased. 
Since the C/P ratio is generally believed to be an index of 
atherogenecity, the rise in C/P ratio in serum is a prerequisite 
for atherogenecity (Gresham et^  al^ . / 1965). A compound capable 
of lowering C/P ratio will, therefore, help not only in normal-
izing tissue lipid levels but also atherosclerotic conditions. 
In our studies, the average C/P ratio, in lower single, higher 
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single or the respective combined doses of the two compounds 
decreased in serxim, liver and aorta, except liver and aorta 
of animals treated with 10 mg HMG/kg. The dose-response 
effect of HMG was also observed in C/P ratio in seriam and 
aorta. The same was true for nicotinic acid in seriom. The 
cholesterol:triglyceride ratio (C/T) increased in serxom 
and liver of animals treated with any dose of HMG or nicotinic 
acid. The observed HMG-induced decrease in lowering of 
various lipid parameters and C/P ratio as well as an increase 
in C/T ratio is in agreement with the earlier findings of 
Beg and Siddiqi (1968) and Yousufzai (19 76). The hypolipidemic 
response of HMG even for liver and aorta lipids is, therefore, 
established. 
For a number of years, investigations on the mechanism 
of fat absorption by the intestine have been primarily con-
cerned with the analysis of the contents of the digestive 
tract and thoracic duct lymph following a fat meal. Transport 
of exogenous triglycerides in chylomicrons is highly efficient 
so that chylomicronia ensues within few hours after each fatty 
meal. This process can account for transport of as much as 
several hundred grams of triglycerides daily. The pathway of 
transport of triglycerides in blood plasma and its regulation 
provides a reasonably firm basis for evaluating the action 
of drugs that reduce triglyceride levels. 
It has been suggested that fructose in drinking water 
increases the intestinal absorption of lipids especially 
75 
triglycerides. Similar findings have been observed in this 
laboratory (Yousufzai, 1976). They have found that HMG 
reduces cholesterol, triglyceride and phospholipid levels in 
whole serum, serum 3-lipoproteins and liver of rats receiving 
10% fructose in drinking water. In accord with Duhault et_ al. 
(1976) the intestinal absorption of olive oil increases serum 
lipids especially triglycerides. The data given in Table 4 
confirm the findings of Duhault et al^ . , that the oral adminis-
tration of olive oil produces hyperlipidemic condition in rats. 
At 2 and 4 hr after administration of olive oil, there was no 
major difference in rise of lipid levels in serum. Oral 
administration of HMG significantly reduced the rise in these 
lipids. HMG treatment for 6 hr was more effective in counter-
acting olive oil-induced hyperlipidemia in rats. Among several 
mechanisms which could explain the increase in intestinal 
absorption of fat and thereby produce hypertriglyceridemic 
conditions in rats on oral administration of olive oil, the 
influx of exogenous fatty acids of olive oil could be an 
important factor in stimulating the VLDL synthesis in the 
intestine as well as in liver (Nikkila, 1969) . Since HMG is 
capable of counteracting the olive oil-induced hypertrigly-
ceridemic effect only it would be reasonable to conclude that 
like nicotinic acid (Levy et_ al^ . , 1972) HMG could decrease 
VLDL production. This would also explain the observed 
decrease in body weight of rats treated with HMG and given 
high fat (Yousufzai and Siddiqi, 1977b) or high 
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carbohydrate diets (Yousufzai and Siddiqi, 19 7 7a), which 
was interpreted in terms of HMG to counteract high fat or 
high carbohydrate-induced obesity. The possibility of its 
inhibitory effect on pancreatic lipase (Bernier, 1975) and 
phosphatides phosphohydrolase (Bowley and Brindly, 19 76), 
however, can not be ruled out. 
There is now sufficient evidence that the diabetic 
condition increases the risk of atherosclerosis in coronary, 
cerebral and peripheral arteries (Carlson and Bottiger, 19 72; 
Garcia et al^ ., 1974) . Experimental diabetes induced in 
laboratory animals by alloxan or streptozotocin is accompanied 
by marked changes in lipid metabolism, notably an elevation 
in seriom triglycerides (Meier et al_. , 19 72; Reaven and Reaven, 
1974) and a decrease in hepatic cholesterol synthesis (Cayen 
et al., 1975). These abnormalities are associated with 
atherosclerosis in diabetes (Santen, 1972). It 
has been reported that hypertriglyceridemia of the diabetic 
rat is caused by an accelerated removal mechanism of VLDL 
triglycerides (Whiting et. al_-, 19 77). Other studies indicate, 
however, that increased VLDL synthesis is the most important 
cause of hypertriglyceridemia in human diabetes (Nikkila and 
Kekki, 1973). The decrease in cholesterol synthesis was 
ascribed to the suppression of HMG-CoA reductase (White, 1970). 
In view of these changes we considered it of interest to 
use the alloxan-induced diabetic rats to investigate further 
the mode(s) of action of HMG. The diabetic state induced in 
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rats was characterized by hyperglucosuria, hyperglycemia, 
increased food intake and by a decrease in body weight gain 
and liver weight. As shown in Table 5, diabetic rats had 
increase in serum cholesterol and this was associated with a 
comparable increase in phospholipid levels. Hepatic cholesterol 
showed a small decrease. This could be due to the inhibition 
of cholesterol biosynthesis in diabetes. The increase in serum 
cholesterol coupled with the decrease in hepatic cholesterol 
synthesis found in diabetic rats can be explained by redis-
tribution of cholesterol from liver to blood and by impaired 
catabolism and removal of cholesterol from the body (Sadahiro 
et al. , 1970). Administration of HMG caused a significant 
decrease in serum cholesterol levels in diabetic rats whose 
rate of hepatic cholesterol synthesis was already suppressed 
(V'Jhite, 1970). A significant decrease in cholesterol was 
observed in liver. This suggests that treatment with HMG 
suppressed the remaining cholesterogenic activity via inhibition 
of HMG-CoA reductase (Beg and Lupien, 1972). The hypertri-
glyceridemia observed in diabetic rats in the present study 
is in accordance with previous reports (Meier et al_., 1972; 
Reaven and Reaven, 19 74). Liver triglyceride and phospholipid 
levels were virtually unaltered. Intraperitoneal administra-
tion of HMG lowered the elevated serum triglycerides; the 
extent of this antihypertriglyceridemic effect was comparable 
to the effect produced by HMG in normal rats (Beg and Siddiqi,"' 
1968). The opposite effects of diabetes and HMG on seruiti \ 
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triglycerides in rats may be due to the opposite effects on 
a-glycerophosphate dehydrogenase. This suggestion is based on 
the reports that experimental diabetes increases hepatic tri-
glyceride synthesis by decreasing the activity of a-glycero-
phosphate dehydrogenase (Corder and Kalkhoff, 1969). Further-
more, since the activity of lipoprotein lipase and/or adipolytic 
lipase is decreased in diabetic rats at the site of tri-
glyceride hydrolysis (Pykalisto et_ aj^ . , 1974; Van Tol, 1977), 
the opposing effects of HMG on these enzymes in seriom could 
provide an additional contribution to the antihypertriglyceri-
demic activity of HMG in diabetic rats. The circulating free 
fatty acid levels increased in diabetic rats". This is in 
agreement with the earlier findings that the free fatty acid 
release from depot fat is increased in diabetes (Cayen et al^ ., 
19 75). The free fatty acid levels were decreased by treatment 
with HMG. This finding suggests that the hypolipidemic 
activity of HMG could be due to an inhibition of free fatty 
acid release from adipose tissue. The mean glucose values 
of diabetic animals receiving HMG were also much smaller 
than those of untreated diabetic controls. It was interesting 
to note that the physical condition of diabetic rats improved 
on HMG treatment. This suggests that the administration of 
HMG improved glucose tolerance without associated weight loss 
(Jaillard and Riveline, 1975). 
One experimental approach in the study of regulation 
of lipoprotein metabolism is through the exploration of the 
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mechanism of fatty liver production. An inverse relationship 
between hepatic triglyceride acciomulation and serum lipoprotein 
concentration has been demonstrated in rats treated with carbon 
tetrachloride (Recknagel, 1967). In the present study it was 
observed that animals treated with carbon tetrachloride showed 
tremendous rise in hepatic lipids especially triglycerides. 
There was a simultaneous decrease in these lipids in ser\am. 
This could be due to a defective enhancement in the synthesis 
and/or availability of lipid in liver for lipoprotein synthesis. 
A defect in conjugation of protein with lipid moities or a 
blockage in the secretary mechanism of lipoproteins in the 
endoplasmic reticulum of liver is also possible (Lombardi, 
1965; Vaishwanar, 1976). 
Essentially all the drugs under investigation as 
hypolipidemic agents prevent orotic acid fatty liver. 
Although not yet unequivocally established, it has been 
suggested that such a hypolipidemic effect could arise either 
by counteracting hepatic inhibition of VLDL synthesis or 
fascilitating the release of VLDL from liver to plasma 
(Elwood et_ al_. , 1972) . In a previous study from this 
laboratory, it was reported that like nicotinic acid, choles-
tyramine and pyrazonic acid, KMG failed to prevent orotic 
acid-induced fatty liver in rats (Yousufzai and Siddiqi, 
19 77c) . This observation led to conclude that the hypo-
lipidemic activity of HMG is mediated through the inhibition 
of synthesis of S-lipoproteins. To confirm these results 
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the effect of HMG on carbon tetrachloride - induced fatty liver 
was studied. Like nicotinic acid (Vaishwanar et_ al_. , 1972), 
the administration of HMG to rats reverse the changes in 
different lipid fraction in serum and liver caused by carbon 
tetrachloride. In 48 hr study, the observed per cent change 
was significant only in serum cholesterol and hepatic phos-
pholipids (table 6). In 168 hr study, as evident from table 
7, HMG significantly decreased cholesterol, triglyceride 
and phospholipids in liver. On the other hand, these lipid 
levels were increased in serum. The significant change in 
these lipid levels show that somehow it interferes in 3-
lipoprotein synthesis. It could be postulated that HMG 
was improving the defective synthesis or availability of 
lipids or conjugation mechanism for lipoprotein synthesis. It is 
possible that HMG was fascilitating the secretion of lipo-
proteins from liver to plasma. The observed decrease in 
liver weight due to HMG in carbon tetrachloride treated rats 
was significant in both studies. Unlike orotic acid-induced 
fatty liver, it indicates a beneficial effect of HMG in 
counteracting the fatty liver conditions in rats. No change 
in body weight between HMG-treated and control group, and a 
change in lipid levels in serum and liver suggests that HMG 
probably inhibited the depot fat mobilization, thereby 
decreasing the availability of triglycerides and free fatty 
acids for the synthesis of different lipid fractions in liver. 
Since carbon tetrachloride is known to impair the secretory 
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mechanism of hepatic parenchymal cells (Vaishwanar, 1972) 
and HMG counteracts the fatty liver caused by carbon 
tetrachloride, it appears that HlviG checks the synthesis of 
3-lipoproteins rather than the release of VLDL. However, 
the effect of HMG on release of 6-lipoproteins can not be 
ruled out. 
According to Eaton and Kipnis (1969a, 1969b) cobalt 
ion produces an endogenous hyperlipidemia which is virtually 
indistinguishable from 'carbohydrate-induced lipemia' and is 
independent of dietary considerations. Later on in 1972, 
Eaton reported that endogenous hyperlipidemia of both carbo-
hydrate feeding and cobalt chloride treatment is initiated 
by insulin-mediated stimulation of hepatic protein synthesis 
followed by release of lipid carrying protein into circula-
tion. The serum of rabbits was characterized as grossly 
lipemic with the predominant abnormality being an increase 
in VLDL transport protein and its triglyceride component. 
Our date in table 8 confirm the findings of Eaton 
and others (Lempert and Levina, 1974; Ohmichi, 1977) that 
cobalt chloride produces hyperlipidemic conditions. In this 
study intramuscular administration of cobalt chloride at the 
concentration of 25 mg/kg/day for seven days resulted in a 
marked increase in cholesterol, triglycirides, phospholipids 
and free fatty acids in ser\am and liver. Treatment of rats 
with 50 mg HMG/kg/day effectively counteracted the enhanced 
lipemic response of cobalt chloride. All these lipids 
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decreased significantly in seriim as well as in liver. HMG 
has been found to prevent carbohydrate-induced lipemia 
(Yousufzai and Siddiqi, 1977a). This could either be due to 
inhibition of VLDL synthesis or to VLDL triglyceride release 
in liver. It has been shown that HMG was unable to overcome 
orotic acid-induced fatty liver changes in rats (Yousufzai 
and Siddiqi, 1977c). This may rule out the possibility of HMG 
inhibiting the release of VLDL and LDL. Since lipoproteins 
participate in mobilization of liver lipids (Levy et. al^ . , 
1972; Tzagournis, 1978) and HMG significantly lowers lipids 
in animals receiving cobalt chloride, it appears that HMG 
checks VLDL synthesis rather than the release of VLDL. This 
is also evident from the observation that the decrease in 
serxom lipids was not accompanied by rise in liver lipids as 
reported earlier (Yousufzai and Siddiqi, 1977b). 
Aging in man is associated with a variety of changes 
in lipid metabolism, some of which have been closely linked 
to the development of atherosclerosis. Both intrinsic aging 
processes and the environmental factors (specially diet) 
operative over many years apparently act in concert with 
unknown genetic factors to produce the very prevalent multi-
factorial disease atherosclerosis (Siddiqi and Yousufzai, 
1977). Carlson in 1973 studied the distribution of plasma 
triglycerides and cholesterol in the lipoprotein fractions 
of males aged 30-55 years with myocardial infraction or 
perepheral atherosclerosis. They found that there was an 
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elevation of triglycerides in the VLDL fraction and in LDL 
fraction with increasing age. Cholesterol was significantly 
elevated in the VLDL and to a lesser extent in the LDL. There 
was a consistent decrease in HDL fraction. Subjects over 55 
years of age showed a similar pattern, here considerably 
greater in the myocardial infarction subjects than in those 
with perepheral atherosclerosis. 
The work presented here was performed to demonstrate 
age-related alterations in the responsiveness of mature rats 
to HMG and to emphasize the importance of age as a factor in 
assessing the compound response. Effectiveness of HMG were 
evaluated in 2-3; 5-6; 9-10; and 15-20 months old, male rats. 
As shown in table 9 the concentrations of cholesterol, tri-
glyceride and phospholipid increased with age in serum and 
liver. Administration of HMG to 2-3 month old rats caused a 
significant decrease in serum and liver triglycerides only. 
Cholesterol and phospholipids in serum and liver showed no or 
a small effect. In 5-6 month old rats, HMG administration 
significantly decreased serum and liver triglycerides and 
serum phospholipids. The 9-10 month old rats responded 
slightly greater. They showed significant effect of HMG in 
serxom and liver triglycerides. In this group, serum cholesterol 
was also significantly lowered. Similar results were obtained 
in 15-20 month old rats i.e., cholesterol and triglycerides 
in serum declined significantly and among hepatic lipids, 
the decrease in triglycerides was significant. 
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It has already been established that HMG inhibits 
cholesterol synthesis (Fimognari, 19 64; Beg and Lupien, 1972) 
and may interfere at some stage of fatty acid synthesis like 
CPIB and TPIA (Maragoudakis, 1969). The decrease in serum 
and liver triglycerides caused by HMG administration in all 
groups suggests that like nicotinic acid (Barboriak and Meade, 
1971) and CPIB (Fallon et a^. , 1972) HMG may inhibit the 
mobilization of free fatty acids from endogenous lipid stores. 
This could reduce the uptake of free fatty acid in liver re-
sulting in decreased hepatic formation of VLDL. 
The older animals used in these studies were in no 
sense "old", yet insignificant differences in responsiveness 
between the age groups of approximately 3 and 9 months old 
rats were evident. It is quite likely that 2 week duration 
of HMG treatment was not enough to induce maximal differences 
among various age groups. Several mechanisms are probably 
involved in this phenomenon including alterations in the 
compound distribution, metabolism, elimination and target 
organ sensitivity. Thus, in pharmacological studies, the 
age of the animals employed should be considered as one of 
the experimental variables to be controlled. No change in 
weight gain between control and HMG-treated animals suggest 
that HMG does not retard the growth of young rats. 
Hypolipidemic properties of HMG have been shown in 
rats (Beg and Siddiqi, 1967; 1968; Yousufzai and Siddiqi, 
1976a, 1977b), rabbits (Lupien et al,, 1973a; Yusufi and 
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Siddiqi, 1974) and man (Lupien, 1973b; Yousufzai and Siddiqi, 
1976a,b). The experiment in rats and rabbits indicated that 
HMG decreased lipid levels in serum, liver and aorta and pre-
vented the atheromatous plaque formation. Since no informa-
tion was available about the hypolipidemic effect of HMG in 
birds, we report here that HMG has lipid lowering effect in 
normocholesterolemic chickens also. The results in table 10 
show that the oral administration of HMG at the concentration 
of 50 mg/kg for 1 week to normocholesterolemic chickens 
significantly lowered cholesterol and triglyceride levels 
in serum. The free fatty acids and phospholipids were in-
significantly decreased, which might be due to the short 
duration of HMG treatment. It has been known that HMG 
inhibits the biosynthesis of cholesterol (Beg and Lupien, 
1972) . Since all the fractions were affected, the action 
seems likely on lipoproteins as suggested by earlier workers 
in this laboratory (Yousufzai and Siddiqi, 1977a). More-
over, reduction was most marked in triglycerides, suggesting 
an effect on VLDL and LDL. Because HMG exerts profound 
hypolipidemic effect in chickens, the lipid-lowering action 
does not appear to be species-specific. 
Several cyclic analogues of clofibrate have been 
reported by Witiak et_ al. , 1975 and Goldberg et al. , 1977, 
to possess hypotriglyceridemic and/or hypocholesterolemic 
properties in the Triton WR-1339-induced hyperlipidemic rat 
model. Schurr (1972) have described a screening procedure 
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for hypolipidemic compounds in Triton WR-1339-induced 
hyperlipidemic rats. Garattini et al., (1961) and Paoletti 
(1962) suggested the use of Triton-induced hyperlipidemia as 
an approach to screen or to differentiate the mechanism of 
action of hypolipidemic drugs. Their tests were of two 
kinds. In the 'first phase' test the drug was given i.p.at 
the same time as Triton, and a decrease in hyperlipidemia 
8 hr later compared to controls was taken as evidence of 
activity resulting from an inhibition of increased synthesis 
of cholesterol and fatty acids. In the 'second phase' test 
the drug was given 2 2-24 hr after Triton, and the decrease in 
blood lipids 8 hr later compared to controls was interpreted 
as an indication of the drugs ability to accelerate lipid 
removal. Yousufzai and Siddiqi (1976a) used Triton-induced 
hyperlipidemia in rats to elucidate the mechanism of action 
of HMG. The results of our experiment in chickens are shown 
in table 11. Administration of Triton produced Hyperlipidemic 
condition in chickens. HMG at both durations (20 hr and 
43 hr post-Triton) significantly decrease the rise in cholesterol, 
triglyceride and phospholipids in serum. However, an insig-
nificant effect was observed in free fatty acids. It was of 
interest that there was not much difference in the per cent 
decrease of various lipid levels 20 hr and 43 hr after Triton 
administration. This suggests that HMG effectively counter-
acts the hyperlipidemic response only when given with Triton. 
This conclusion is in accordance with the earlier findings 
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of Yousufzai and Siddiqi (19 76a) where the animals were rats. 
Among several possibilities of mechanism of action of HMG 
reported earlier, it has been emphasized that hypolipidemic 
response of HMG could involve a shift in lipoprotein spectrum 
(Lupien et. al., 1973a; Yusufi and Siddiqi, 1974). Recently 
it has been shown that HMG has no effect on orotic acid fatty liver 
in rats (Yousufzai and Siddiqi, 19 77c). Since Triton is known 
to physically alter VLDL, and HMG is capable of counteracting 
Triton-induced hyperlipidemia, the possibility of HMG exerting 
its hypolipidemic effect through the inhibition of lipoprotein 
synthesis appears more plausible. Furthermore, the method 
used detects compounds which inhibit lipid biosynthesis or 
its catabolism (Schurr et. a]^. , 1972), the hypolipidemic 
activity of HMG may be mediated through its effect on lipid 
metabolism. Fogelman et_ a]^. / 1975 have recently shown that 
normally 12% of mevalonic acid is catabolized through a 
shunt pathway in mammalian system involving trans-3-methyl-
glutaconyl CoA. A derailment in the operation of this path-
way might explain the hypercholesterolemic condition in 
animals and man. In view of earlier reports on hypolipidemic 
activity of HMG (Lupien, 1973a; Yousufzai and Siddiqi, 1977c) , 
it is tempting to suggest, therefore, that HMG may in some 
way correct the derailed pathway. 
Our studies strengthen the belief that HMG has an 
antihyperlipidemic effect in animals and man. However, much 
work is to be done to arrive at the exact mechanism (s) through 
88 
which HMG exerts its. hypolipidemic and hypolipoproteinemic 
properties. It is tolerable, non-toxic and effective in 
experiments presented in this thesis. This is not surprizing 
as HMG is a natural metabolite arising in_ vivo by deacylation 
of HMG-CoA (Dekker et_ al. , 1958). With these considerations 
the potentiality of HMG as a future drug for CHD is great. 
Further clinical studies are desirable to establish its 
therapeutic value. The multiple action of HMG can be des-
cribed in the following ways. 
Details 
1. Hypercholesterolemic rats 
2. Olive oil-induced hyper-
triglyceridemic rats 
3. Carbon tetrachloride-
induced fatty liver in 
rats 
4. Cobalt chloride-induced 
hyperlipidemic rats 
5. Alloxan-induced diabetic 
rats 
Possible Mode of Action 
Inhibition of cholesterogenesis 
and lipogenesis. 
Inhibition of intestinal 
absorption of fat 
Inhibition of increased tri-
glyceride synthesis 
Inhibition of the activity 
of pancreatic lipase 
Inhibition of VLDL production 
Like nicotinic acid, it in-
hibits the lipoprotein synthesis 
Inhibition of the mobilization 
of depot fat 
Inhibition of VLDL synthesis 
Inhibition of cholesterogenesis 
Increase in the activity of a-
glycerophosphate dehydrogenase 
Increase in the activity of 
lipoprotein lipase 
Inhibition of increased free 
fatty acid release in diabetes 
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Details Possible Mode of Action 
6• Normocholesterolemic rats 
and chickens 
7. Triton-Induced hyperlipi-
demia in chickens 
Inhibition of cholesterogenesis 
and lipogenesis 
Inhibition of increased synthesis 
of cholesterol and fatty acids 
Inhibition of synthesis of lipo-
proteins 
Correction in derailed mevalonic 
acid shunt pathway in mammalian 
system. 
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ABBREVIATIONS 
CHD : coronary heart disease 
CPIB: ethyl p-chlorophenoxyisobutyrate 
HDL : high density lipoproteins 
HLP : hyperlipoproteinemia 
HMG : 3-hydroxy-3-methylglutaric acid 
i.m.: intramuscular 
i.p.: intraperioteneal 
i.v.: intravenous 
LDL : low density lipoproteins 
s.c: subcutaneous 
TPIA: tetralylphenoxyisobutyrate 
VLDL: very low density lipoproteins 
